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SUMMARY 
 
The human SLX4 is a scaffold protein that coordinates multiple partners and it is 
involved in interstrand crosslinks repair, as well as in the resolution of Holliday 
junctions. 
In this thesis I performed for the first time a phospho‐mapping analysis of the 
endogenous SLX4, immunoprecipitated from  untreated or  MMC‐treated cells.  This 
experiment led to the identification of ATM/ATR phospho‐sites, as well as sites that 
could be targeted by proline‐directed kinases. Although the meaning of the SLX4 
phosphorylation is still unclear, it could be possible that this modification affects 
the binding between SLX4 and some of its partners. In this regard, I found that SLX4-
MUS81 interaction is dynamic. The amount of MUS81 in SLX4 immunoprecipitates was 
reduced after exposing cells to genotoxins, such as MMC, CPT, and HU. Moreover cell-
cycle experiments using counterflow centrifugal elutriation showed that the binding 
between the two proteins increases in S/G2 phase.   
In the second section, mass fingerprinting analysis of endogenous SLX4 
immunoprecipitates, showed that the complex binds also to two E3 ligases: the E3 
RING SCFFBXO11 complex and the HECT E3 UBR5 and these interactions were confirmed 
by immunoprecipitation. SCFFBXO11 and UBR5 target their substrates to protein 
degradation, but preliminary experiments showed that the interactions did not affect 
the overall quantity of SLX4 or the binding with its nucleases. 
 
Finally I showed that the endogenous SLX4 interacts with the mismatch repair (MMR) 
complex MSH2-MSH3 by immunoprecipitation. Moreover, from yeast  two hybrid 
assay it appeared that MSH2 directly binds to SLX4 and the binding involves the N-
terminal region of SLX4. If this direct binding will be confirmed, I will investigate 
whether the MSH2-MSH3 complex plays a role in ICL repair or in Holliday junctions 
resolution pathway. 
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1 INTRODUCTION 
 
 
 
1.1 The DNA damage response 
 
Genome integrity is constantly threatened by endogenous and exogenous factors that 
cause DNA damage. DNA damage needs to be repaired quickly in order to avoid errors 
that could lead to genome instability and the development of diseases such as cancer. 
Endogenous factors that cause DNA damage include byproducts of oxidative 
metabolism, such as reactive oxygen species (ROS) that can induce oxidation of DNA 
bases, as well as errors arising from base misincorporation during replication. 
Exogenous factors include UV light which causes pyrimidine dimers that can impede 
the progression of DNA replication and transcription machineries, and ionizing 
radiation which can induce DNA single‐strand and double‐strand breaks. Many drugs 
used in chemotherapy of cancer act by inducing DNA damage and these include 
hydroxyurea (HU) which blocks the replication fork by inhibiting the production of 
dNTPs, and mitomycin‐C (MMC) and cisplatin which can covalently crosslink bases on 
the same (intrastrand) or opposite (interstrand crosslinks) DNA filaments. 
 
 
1.2 Interstrand DNA crosslinks 
 
Interstrand DNA crosslinks (ICLs) are particularly toxic lesions, because they prevent 
the two DNA strands from separating, thereby perturbing DNA replication and 
transcription. In fact, it has been estimated that as few as twenty interstrand crosslinks 
in the mammalian genome can be lethal to cells that lack the ability to remove the 
crosslink (Lawley et al. 1996; Murnane et al. 1981). ICLs are caused by both 
endogenous and exogenous factors. Among the endogenous agents are unsaturated 
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aldehydes and nitric oxide (Kirchner et al. 1992). Unsaturated aldehydes are derived 
from lipid peroxidation and the metabolism of dietary components such as coffee and 
alcohol (Stone et al. 2008; Huang et al. 2010a; Garaycoechea et al. 2012); nitric oxide 
can also be linked to diet as it is a by‐product of nitrates used to preserve meat, but it 
is also a signaling molecule important for vasoregulation (Kirchner et al. 1992; 
Guainazzi et al. 2010). Nitrogen mustards, mitomycin C, psoralen, and platinum 
compounds like cisplatin are exogenous agents that produce a mixture of 
monoadducts and ICLs and they are commonly used in cancer therapy to kill tumor 
cells (Lawley et al. 1996; McHugh et al. 2001). However, these treatments also induce 
ICLs in normal cells (McHugh et al. 2001), and it has been shown an increase in the 
incidence of acute myeloid leukemia (AML) in patients treated with ICL‐inducing 
agents (Tucker et al. 1988; Travis et al. 1999). Regardless of the source of ICLs, cells 
have developed mechanisms to detect and repair these lesions. 
 
 
1.2.1 Repair of interstrand crosslinks 
 
 
The first cohesive model for ICL repair in Escherichia coli was proposed by Ronald Cole 
in 1973. Using cells containing psoralen‐induced ICLs, he proposed a repair mechanism 
that involved a partial excision of the crosslink, followed by strand exchanges between 
homologous filaments (Cole, 1973). In lower eukaryotes, studies performed on S. 
cerevisiae showed the involvement of three distinct pathways: nucleotide excision 
repair (NER), post‐replication repair and homologous recombination (HR) (Jachymczyk 
et al., 1981; Grossman et al., 2001). In mammalian systems the situation appears to be 
more complicated, but progress in understanding the molecular mechanisms of ICL 
repair  have  been  greatly  aided  by  studying  the  human  genetic  disorder  Fanconi 
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Anemia (FA). This is a rare inherited syndrome, with an incidence of 1 to 5 per 106 
births, with clinical features that are very heterogeneous in nature. Patients can 
present with skeletal abnormalities such as hypoplasia of the thumbs and radial 
hypoplasia, skin pigmentation, developmental disorders and cancer such as squamous 
cell carcinoma of the head or neck and hepatocellular carcinoma (Tischkowitz et al., 
2003; Fanconi, 1967; D’andrea et al., 2010). During childhood, most FA patients 
manifest hematological abnormalities: aplastic anemia, myelodysplastic syndrome 
(MDS) and acute myeloid leukemia (AML) (Tischkowitz et al., 2003). Given the 
heterogeneity of the syndrome, a diagnosis based only on clinical features is difficult. 
However in 1988 Auerbach and colleagues developed a test for FA based on the 
hypersensitivity of FA lymphocytes to crosslinking drugs. Agents like mitomycin C or 
diepoxybutane induce chromosomal abnormalities in FA cells such as radial 
chromosomes and chromosome breakage (Auerbach et al., 1988). This observation led 
to the assumption that the FA syndrome is linked with the interstrand crosslink repair 
pathway. 
 
 
ICL repair in mammalian is still poorly understood but it is clear that it is a complicated 
process that involves the cooperation of multiple pathways: the FA pathway, 
homologous recombination (HR), translesion synthesis (TLS) and nucleotide excision 
repair (NER) (McCabe et al., 2009; D’andrea et al., 2012). ICL repair can take place in 
G1 phase of the cell cycle (Wang et al., 2001; Muniandy et al., 2009) but it is thought 
that the predominant mode of repair occurs during the S phase, induced by the 
collision of one of more replication forks with the ICL (Akkari et al., 2001; Rothfuss et 
al., 2004). At present, there are three major models that have been put forward to 
account for replication‐coupled ICL repair. In the first, repair initiates when a single 
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replication fork stalls at an ICL lesion, and DNA replication resumes when the repair is 
completed by homologous recombination (Niedernhofer et al., 2005). The second 
model is somewhat similar to the first but the stalled replisome traverses the ICL with 
the help of FANCM, and the repair of the ICL itself is post‐replicative (Huang et al. 
2013). In the third model, two replication forks stall on an ICL and as in the second 
model, the repair is post‐replicative (Raschle et al., 2008) (Fig.1). 
 
 
1.2.1.1         Models to explain ICL repair 
 
In the first model, the collision of the replication fork with the ICL recruits various FA 
proteins, possibly starting with FANCM. This protein has a translocase activity, which 
might remodel the fork, leading to recruitment of the FA core complex in collaboration 
with FAAP20 and RNF8 (Gari, Decaillet et al. 2008; Yan, Guo et al. 2012). The FA core 
complex includes nine polypeptides that together comprise an E3 ubiquitin ligase 
which ubiquitinates two paralogous FA proteins, FANCD2 and FANCI (Alpi and Patel 
2009). As discussed later, ubiquitination of FANCD2 signals fork stalling and helps to 
initiate ICL repair. An early step of ICL repair is “unhooking” which involves dual 
incisions on either side of the ICL. This results in a “flipping out” of the ICL and fork 
breakage leading to generation of a one‐ended double strand break (Fig.1, first 
model). The gap created by unhooking is filled in by TLS past the damaged 
oligonucleotide, which is subsequently removed by a NER mediated cleavage. Finally 
HR restores the replication fork so that DNA replication can resume (Niedernhofer, 
Lalai et al. 2005). In the second model, repair of the ICL is uncoupled from DNA 
replication. DNA fiber analysis shows that the replication machinery can traverse 
an ICL lesion, in a manner that requires FANCM. When a replication fork stalls by 
an ICL, FANCM might translocate the all complex past the ICL onto the non‐replicated 
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strands (Fig.1, second model). This would allow cells to restart the replication and to 
repair the ICL lesion by postreplication pathways (Huang, Liu et al. 2013). 
 
 
The third model, proposed by Räschle and colleagues, comes from experiments carried 
out in cell‐free extracts of Xenopus that monitor the repair of a plasmid bearing a site‐ 
specific ICL. The plasmid is small, with a single origin of replication and both forks 
emanating from this origin encounter the ICL. This system has been very useful in 
visualizing steps involved in ICL repair, but by necessity it invokes two forks hitting the 
ICL. In  this  model,  the two  replication  forks  encountering the ICL  stall  around  20 
nucleotides before the crosslink (Fig.1, third model). Prior to the uncoupling step, a TLS 
polymerase extends the nascent strand within one nucleotide from the ICL and only 
later on the ICL incision step takes place. After that, a nucleotide is inserted across 
from the damaged template base and then the leading strand is extended beyond the 
ICL by a translesion DNA polymerase. Finally the lesion is excised and HR restores the 
replication fork. As mentioned before, the model was proposed based on experiments 
performed using a cell‐free system based on Xenopus egg extracts using plasmids 
containing single nitrogen mustard‐like or cisplatin ICL. Although this system is useful 
for studying a single ICL lesion, it is unclear whether it would accurately reflect ICL 
repair in vivo (Raschle et al., 2008). 
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1.3 FA and FA‐associated proteins 
 
As mentioned before, FA syndrome is linked with the ICL repair pathway, and many 
genes essential to the repair of ICLs were discovered to be mutated in FA patients. 
Currently  there  are  16  FANC  complementation  groups:  FANCA,  FANCB,  FANCC, 
FANCD1,  FANCD2,  FANCE,  FANCF,  FANCG,  FANCI,  FANCJ,  FANCL,  FANCM,  FANCN, 
FANCO, FANCP and FANCQ. Some of the proteins are required for sensing the damage 
and others are directly implicated in the repair of the ICL lesion (Table 1). 
 
 
 
 
Table 1: The sixteen complementation groups of FA and their related activity in the FA 
pathway. 
 
 
 
 
The FANCM subunit initiates the pathway possibly by binding to DNA discontinuities at 
the stalled fork; exactly how FANCM is recruited is unclear but it appears to involve 
other proteins (Ciccia et al. 2007; Yan et al. 2010; Singh et al. 2010). FANCM is a 
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member of the XPF family of endonucleases together with XPF‐ERCC1, MUS81‐EME1, 
and MUS81‐EME2. In eukaryotes all the members of this family exist as heterodimers 
consisting of an active‐nuclease subunit (XPF, MUS81) and a non‐catalytic subunit 
(ERCC1,  EME1,  EME2).  The  catalytic  form  presents  a  core  Excision  Repair  Cross 
Complementation group  4  (ERCC4) endonuclease  domain  and a  Helix‐hairpin‐Helix 
 
(HhH) domain. The non‐catalytic counterpart retains the ERCC4 module, but lacks key 
residues for the endonuclease activity (Ciccia et al. 2008). Although FANCM is an XPF‐ 
like protein, it lacks the endonuclease activity, but it binds to branched DNA structures 
in vitro and exhibits an ATP‐dependent translocase activity. In 2007 Steve West’s lab 
discovered FAAP24, the ERCC1‐like partner of FANCM (Ciccia et al. 2007). The binding 
of FAAP24 to FANCM stabilizes the association of FANCM with single stranded DNA 
and is thought to lead to the recruitment of the FA core complex to chromatin in an S‐ 
phase dependent manner (Ciccia et al. 2007; Kim et al. 2008). Moreover, the binding of 
FANCM to the chromatin is assisted by two histone‐fold containing proteins, MHF1 and 
MHF2 that stimulates replication fork remodelling (Yan et al. 2010; Singh et al. 2010). 
 
 
The correct assembly of the core complex is crucial for proper downstream signaling 
such as the monoubiquitination of the FANCD2/FANCI complex (also called the “ID” 
complex). The ubiquitination of FANCD2 by the FA core complex is catalyzed by the E3 
RING‐type ubiquitin ligase FANCL (Alpi et al. 2009). FANCL belongs to the FA core 
complex together with seven other FANC proteins (see Table 1), but FANCL seems to 
be the only component with intrinsic ligase activity (Alpi et al. 2009; Meetei et al. 
2003). The monoubiquitination of FANCD2 by FANCL is required for the targeting and 
accumulation of FANCD2 in nuclear foci at sites of DNA damage (Garcia et al. 2001; 
Taniguchi et al. 2002). Ubiquitination of FANCD2 was also found to be required for the 
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unhooking, translesion synthesis and homologous recombination steps of ICL repair, at 
least in the Xenopus cell‐free system (Knipscheer et al. 2009; Räschle et al. 2008). 
 
 
The encounter of an ICL by the replication fork, leads to the recruitment of nucleases. 
FAN1, which displays both a 5’‐3’ exonuclease and 5’ flap endonuclease activity, is 
recruited to the stalled fork via its interaction with the monoubiquitinated FANCD2 
(MacKay et al. 2010). This binding requires the UBZ4‐type ubiquitin‐binding zinc finger 
domain present on FAN1 (Liu et al. 2010; Smogorzewska et al. 2010; Kratz et al. 2010; 
MacKay et al. 2010). 
 
 
The role of FAN1 in ICL repair is not clearly understood: although FAN1 is a nuclease 
and is recruited by FANCD2, it is probably not required for ICL unhooking. Several 
laboratories proposed that the initiation of the unhooking might be mediated by the 
structure‐specific nuclease MUS81‐EME1 (Hanada et al. 2006; Hanada et al. 2007), 
followed by a second incision by the heterodimeric nuclease XPF‐ERCC1 (Bergstralh et 
al. 2008; Bhagwat et al. 2009). However, Wang and colleagues found evidence of a 
third nuclease, SNM1A that participates in the unhooking event (Wang et al. 2011). In 
this model, the first incision is mediated by XPF‐ERCC1, followed by an SNM1A 
exonucleolytic digestion of the cross‐linked oligonucleotide. In this context, MUS81‐ 
EME1 requirement could be limited to a backup activity, in case of a failure in the XPF‐ 
SNM1A pathway. 
 
 
The incision of the ICL leads to the formation of a DSB in the lagging strand and an 
unhooked ICL on the leading strand and TLS polymerases, like REV1 and Pol ζ extend 
18  
 
 
across the adduct (Sharma and Canman 2012). Finally homologous recombination 
completes the reaction (Fig.1). 
 
 
1.4 The mammalian SLX4 complex 
 
SLX4 is a scaffold protein that coordinates a multi‐protein complex involved in repair of 
DNA interstrand crosslinks. SLX4 has no obvious catalytic motifs but it is contains 
several modular domains (Fig. 2). At the N‐terminus there are two UBZ4 domains 
(ubiquitin‐binding zinc finger domain 4), followed by an MLR domain (MEI9‐ 
Interaction‐Like Region), a BTB/POZ domain (Broad‐Complex, Tramtrack and Brick a 
brax/Poxvirus and Zinc finger), a SAP domain (SAF‐A/B, Acinus and PIAS), and at the C‐ 
terminal end there is an HtH motif (Helix turn Helix). SLX4 interacts with three 
structure‐selective endonucleases: XPF‐ERCC1, MUS81‐EME1 and SLX1, which bind to 
the MLR, SAP and HtH domains respectively (Fekairi et al., 2009; Kim et al., 2013; 
Svendsen et al., 2009; Castor et al. 2013). SLX4 also associates with the mismatch 
repair complex (MSH2‐MSH3), shelterin factors TRF2‐RAP1, the nuclease 
hSNM1B/Apollo (Salewsky et al., 2012), the protein kinase PLK1 and an 
uncharacterized protein, C20ORF94 (Svendsen et al., 2009) (Fig.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: SLX4 complex showing all the known SLX4 domains and interactors. 
The positions of Apollo and C24ORF94 on the scaffold are still unknown. 
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1.5 SLX4 complex in ICL repair 
 
The importance of SLX4 in ICL repair was underlined by two main observations. First of 
all cells depleted of SLX4 are sensitive to ICL drugs, like camptothecin and MMC 
(Svendsen et al., 2009; Muñoz et al., 2009), secondly and most importantly it has been 
discovered that bi‐allelic mutations in SLX4 cause Fanconi Anemia (Stoepker et al., 
2011; Kim et al., 2011; Kim et al., 2013). Hence, SLX4 was characterized as a recent 
addition to the FA group of proteins and is sometimes referred to as FANCP on this 
basis. 
 
 
A range of SLX4 mutations have been identified in FA (Stoepker et al., 2011; Kim et al., 
2011). In some patients, cells have been found to express very low concentrations of a 
truncated form of SLX4, which retained all known modules, and which was capable of 
interacting with XPF‐ERCC1, MUS81‐EME1 and SLX1 (Stoepker et al., 2011; Kim et al., 
2011). In three siblings from a different family, the level of SLX4 expression was not 
altered but the protein carried a small deletion that removed a fragment containing 
part of UBZ1 and all UBZ2 domain (Stoepker et al., 2011; Kim et al., 2011). These data 
indicate the SLX4 UBZ domains are required for ICL repair. Although the precise role of 
the UBZ domains still need to be unraveled, analysis from the Rouse lab found that the 
UBZ1 binds to K63‐linked polyubiquitin chains and it is the key domain required for the 
recruitment of SLX4 at sites of DNA damage. However the recruitment seems to be 
independent of FANCD2 (JR, personal communication), despite reports to the contrary 
for SLX4 in chicken DT‐40 cells (Yamamoto, Kobayashi et al. 2011). 
 
It is not clear at what stage of ICL repair SLX4 acts. In cells lacking, or depleted of SLX4, 
FANCD2 is ubiquitinated normally and double strand breaks are induced. However, a 
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subset of these breaks persists indefinitely and cells die (Munoz et al., 2009). A role for 
unhooking for SLX4, for example by COMET assay has not been reported, but the data 
above could be interpreted to mean that SLX4 is required for the completion of HR at 
the final stages of ICL repair. This is especially likely given that the SLX4 complex has 
been strongly implicated in late‐stage DNA intermediate processing in HR outside of 
ICL repair, as discussed below. 
 
 
1.6 SLX4 complex in resolution of HJs 
 
Homologous recombination (HR) is a conserved mechanism for repairing DNA double‐ 
strand breaks during meiosis and unscheduled DNA breaks. Perhaps the most 
important function for HR is the repair of DSBs produced by stalled or collapsed 
replication forks. Holliday junctions (HJs) are four way DNA intermediates that arise 
during homologous recombination, points at which two chromatids become 
topologically linked. These structures must be removed, as their persistence through 
mitosis would prevent chromosome segregation. Two major pathways have been 
described for the removal of HJs in mitotic mammalian cells: dissolution and 
resolution. 
 
Dissolution of double HJs is mediated by the BTR complex that comprises the RecQ‐ 
type helicase BLM, which forms a four subunit complex together with DNA 
topoisomerase III, RMI1 and RMI2 (Wu et al., 2003). This mode of HJ removal involves 
only non‐crossover products (Fig.3) (Wu et al., 2003). It is probably for this reason that 
dissolution is the dominant HJ removal pathway in mitotic cells, to avoid loss‐of‐ 
heterozygosity that would compromise fitness. In this light, mutations in BLM cause 
Bloom’s syndrome (BS), a recessive disorder characterized by cancer predisposition 
21  
(Mohaghegh and Hickson 2001). Cells from BS patients show increased loss of 
heterozygosity, and a high degree of sister chromatin exchange (SCE) probably caused 
by increased crossover frequency (Chaganti, Schonberg et al. 1974; Wu et al. 2003, 
2006). 
 
 
The resolution of HJs that escape dissolution is mediated by specialized endonucleases 
that cleave DNA intermediates, yielding to either crossover or non‐crossover products. 
In human cells these endonucleases are MUS1‐EME1 (Chen et al., 2001; Ciccia et al., 
2003), SLX1 (Fekairi et al., 2009; Munoz et al., 2009; Svendsen et al., 2009), and GEN1 
(Ip et al., 2008; Matos et al., 2011) (Fig.3). These enzymes have different in vitro 
substrates specificities. GEN1 is a canonical HJ resolvase that cleaves 4‐way DNA 
junctions symmetrically, and among the three, it is the only nuclease that does not 
bind to the SLX4 scaffold. The second nuclease, MUS81‐EME1 belongs to the ERCC4 
family of endonucleases and as for XPF‐ERCC1, it is composed of a catalytic subunit 
(MUS81) and a non‐catalytic partner (EME1) (Ciccia et al., 2003). The complex has a 
preference for 3’‐flaps, replication forks and nicked HJs, but only weakly cleaves intact 
HJs (Ciccia et al., 2003). SLX1 is the third enonuclease involved in the resolution 
pathway, it belongs to a family of UvrC‐type endonucleases and it consists of a URI 
nucleases domain and a PHD‐type Zinc finger motif (Aravind et al., 2001). In human 
cells it is stable only in complex with SLX4, and it cleave HJs, replication forks, and 3’‐5’ 
flaps (Fekairi et al., 2009; Munoz et al., 2009; Svendsen et al., 2009). 
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Figure 3: Repair of DSBs by either the recombinogenic or the non‐recombinogenic pathways. 
 
(Adapted from Svedsen and Harper, 2010). 
 
 
In vitro and in vivo experiments demonstrated that the SLX4 complex plays a role in 
the resolution of HJs in human cells and this activity resides in its C‐terminal region 
where MUS81 and SLX1 bind (Svendsen et al., 2009). The spatial proximity of MUS81 
and SLX1 on SLX4 coordinates the combined and temporally regulated cleavage of HJs 
by the two nucleases. In the current model, SLX1 acts first by nicking the HJ, then the 
nicked intermediate is acted upon by MUS81 to produce linear duplexes (Wyatt et al., 
2013; Castor et al., 2013). In 2013 the West and Rouse labs gave new insights into the 
in vivo regulation of HJ resolutions both in human and in murine systems (Wyatt et al., 
2013; Castor et al., 2013). 
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In Bloom’s Syndrome cells, the frequency of sister chromatid exchanges is enhanced 
compared to normal cells due to deficiency in the dissolution pathway. Therefore BS 
cells can be used as a read‐out to look for agents involved in the in vivo resolution of 
HJs. By introducing siRNA against endonucleases (SLX4, SLX1, MUS81, GEN1) that act in 
the resolution pathway into BS cells, West and colleagues found that the resolution of 
HJs requires two distinct pathways: one mediated by MUS81‐SLX1‐SLX4 complex and 
another pathway where GEN1 is active (Wyatt et al., 2013). Using a murine system, the 
Rouse lab found that SLX1 and MUS81‐EME1 are epistatic in the resolution of HJs 
escaping the dissolution pathway, consistent with the results from West’s lab (Castor 
et al., 2013). 
 
 
However in ICL repair, it appears that only the SLX1‐SLX4 interaction and not the 
MUS81‐SLX4 interaction is required for ICLs repair and this repair involves the 
processing of structures other than HJs (Castor et al., 2013). Hence, it has been 
proposed that whereas in mitosis the resolution pathway mediated by nucleases acts 
when HJs escape dissolution by BLM helicase, in meiosis the resolving mechanism 
dominates. However, it is not yet clear which nuclease(s) resolve HJs in mammalian 
cells. 
 
 
1.7 Impact of SLX4 scaffold on the associated nucleases 
SLX4 has no obvious catalytic motifs, and instead it appears to have a more structural 
role, coordinating the assembly of a DNA repair complex, and interacting with three 
separate nucleases as described above. As mentioned in the previous section, SLX4 
coordinates the nuclease activity of MUS81 and SLX1 in the resolution of HJs, by 
bringing the two proteins close together (Wyatt et al., 2013; Castor et al., 2013). 
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However, SLX4 mutants that cannot interact with MUS81 are ICL repair proficient (at 
least in mouse cells), and in this system, SLX4 mutants that cannot interact with SLX1 
show partial defects (Castor et al., 2013). Therefore the role of SLX4 in ICL repair must 
involve interaction with a protein other than SLX1 and MUS81, such as XPF‐ERCC1. 
 
 
In humans, the XPF‐ERCC1 complex is required in the NER pathway, a mechanism that 
repairs UV‐induced lesions (Ciccia et al., 2008). Mutations on XPF or ERCC1 cause 
xeroderma pigmentosum (XP) an inherited disease characterized by sensitivity to UV 
radiation and sun‐induced skin cancer (Cleaver et al., 2005). Mutations in XPF also 
cause striking sensitivity to ICL‐inducing agents, in contrast to other NER mutants 
(Niedernhofer, Odijk et al. 2004). Jan Hoeijmakers lab described an XPF mutation in a 
progeroid syndrome XFE that caused pronounced ICL sensitivity and only mild UV 
sensitivity (Niedernhofer, Garinis et al. 2006). Thus it appears possible to separate the 
role of XPF in UV repair from ICL repair. On that note, size exclusion chromatography 
of cell extracts shows that the human XPF‐ERCC1 is present in two distinct cellular 
pools. One co‐elutes in a large molecular complex together with the SLX4 scaffold 
(Munoz et al, 2009; Stoepker et al., 2011); this fraction appears to not be involved 
in the NER mechanism, as human cells depleted of SLX4 are not sensible to UV light 
(Munoz et al. 2009; Feikairi et al. 2009). The pool of XPF‐ERCC1 present in the second 
fraction, elutes later upon gel filtration and represents a smaller complex; most 
importantly it is free of SLX4 and probably represents for the NER (Muñoz et al., 
2009). Therefore the pool of XPF‐ERCC1 binding to SLX4 appears to be required for 
ICL repair only. A recent study concluded that the role of SLX4 in ICL repair involves 
XPF‐ERCC1 only, because a fragment of SLX4 lacking amino acids 1‐499, that did not 
interact with XPF‐ERCC1, did not rescue the mitomycin‐C sensitivity of 
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SLX4‐hypomorphic MEFs (Crossan, van der Weyden et al. 2011). However, the first 
499 amino acids of SLX4 also contain two ubiquitin‐binding domains that are vital 
for ICL repair but that are not required for SLX4‐XPF interaction (Kim, Lach et al. 
2011; Stoepker, Hain et al. 2011). 
 
 
In budding yeast the interaction of Slx4 with XPF‐ERCC1 (Rad1‐Rad10) is required in 
the single‐strand annealing pathway, a mechanism involved in the repair of DNA 
double‐strand breaks (DSBs) that occur between repetitive sequences. As shown in 
Fig.4, in this pathway the DSB undergoes an exonuclease‐mediated 5’‐end resection to 
generate 3’ single‐stranded DNA tails in which complementary strands of the 
duplicated sequence are exposed (a). The strands are then annealed (b) resulting in a 
structure containing 3’non‐homologous tails that need to be cleaved (c) to restore the 
double filament (d). 
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Figure 4: Schematic view of the SSA annealing pathway. (From Ciccia et al., 2008) 
 
 
 
Experiments using the HO endonuclease to induce DSBs between repetitive elements 
showed that Rad1‐Rad10 is the endonuclease required for the cleavage of 3’ tails 
(Fishman et al., 1992), and similar experiments carried on mammalian cells have 
shown the same role for XPF‐ERCC1 (Minawi et al., 2008). In yeast Slx4 was shown to 
interact with Rad1‐Rad10 and to be essential for Rad1‐Rad10 function in SSA and HR 
but not NER (Flott et al., 2007). Further analysis showed that Slx4 is recruited in the 
proximity of persistent 3’ non homologous (NH) tails, and Slx4 deletion reduced SSA 
efficiency by impairing the removal of 3’ non‐homologous tail (Flott et al., 2007; Li et 
al., 2008). At present it is not clear why Slx4 is required for NH tail cleavage in SSA, or 
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what it might do to facilitate cleavage by Rad1‐Rad10. It is unlikely that Slx4 recruits 
Rad1‐Rad10 to 3’ flaps, as another protein, Saw1 mediates this role (Flott et al., 2007; 
Li et al., 2008). Another possibility is that it might be required for the proper 
positioning of Rad1‐Rad10 on DNA by deforming the DNA substrate or it could direct 
the assembly or disassembly of one of the other SSA factors. 
 
 
In human cells, a direct contribution of SLX4 in the SSA pathway has not been reported 
yet. SLX4 binds not only to XPF‐ERCC1, but also to MSH2‐MSH3, a key complex in the 
mismatch repair (MMR) system (Svendsen et al., 2009). The MMR machinery is 
required to recognize and repair insertion/deletion loops (IDLs) and base‐base 
mismatches that escape from the proofreading activity of DNA polymerases (Jiricny, 
2006). MSH2‐MSH3 is the heterodimer that first recognizes and binds to mismatched 
DNA, and starts the DNA‐repairing cascade (Kunkel et al., 2005; Lyer et al., 2006; 
Jiricny, 2006). Interestingly, Msh2 physically interacts with Rad1‐Rad10, independently 
of other MMR factors (Bertrand et al., 1998). Further in vitro and in vivo experiments 
showed that Msh2 in complex with Msh3 is required in gene conversion and single 
strand annealing pathway (Sugawara et al., 1997), where it most probably stabilizes 
structure intermediates and therefore facilitates the recruitment and cleavage activity 
of Rad1‐Rad10 (Sugawara et al., 1997; Evans et al., 2000). It will be interesting to tie 
these observations together and to test the role of SLX4 in SSA in mammals. 
 
 
1.8 SLX4 complex in the control of telomeres 
In mammalian cells, beside the three structure specific endonucleases (XPF‐ERCC1, 
MUS81‐EME1, SLX1), there are other proteins that interact with SLX4 which are not 
directly involved in the repair of ICLs. Together with the discovery of the association of 
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MSH2‐MSH3 with SLX4, the same  proteomic analysis showed TRF2‐RAP1 as novel 
factors belonging to the SLX4 complex (Svedsen et al., 2009). TRF2 and its constitutive 
binding partner RAP1 are part of a six‐protein complex called shelterin. All the 
shelterin factors reside at telomeres and do not seem to localize elsewhere in the 
nucleus (Palm et al., 2008). 
 
 
Mammalian telomeres are DNA‐protein structures that protect chromosome  ends 
from degradation and repair. Telomeres are double stranded filaments constituted of 
an array of TTAGGG sequence that varies in length (2‐200 kb. A striking feature of 
these chromosome‐ends structures is that the 3’ filament (also called G‐strand, 
because it is rich in guanosine) is longer than the 5’ end (C strand), with an overhang of 
5‐500 nt. Shelterin is specific for telomeric DNA because it recognizes the TTAGGG 
repeats and their association with telomeres promotes the so‐called “t‐loop” 
formation. In this DNA configuration, the 3’ overhang invades the duplex region of 
telomeric DNA and base pairs with the C‐strand (Griffith et al., 1999). The purpose of 
the structure is to sequester the chromosome end from the DNA damage response 
pathway. Hence, the shelterin enables cells to distinguish natural chromosome ends 
from DNA breaks, avoiding the activation of DNA damage pathways that would 
otherwise trim the chromosomes leading to a genetic catastrophe. 
 
The interaction between SLX4 and TRF2‐RAP1 complex suggested that SLX4 might 
function at the level of telomeres, and this hypothesis was strengthened by the fact 
that an overexpressed form of SLX4 colocalizes with shelterin in a specialized HeLa cell 
line with extra‐long telomeres (Svedsen et al., 2009). In 2013 two different laboratories 
showed   the   association   of   endogenous   SLX4   with   telomeres,   by   chromatin 
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immunoprecipitation (ChIP) and immunofluorescence (IF) (Wan et al., 2013; Wilson et 
al., 2013). 
 
 
The length of telomeres is determined by the balanced between telomere lengthening 
and shortening mechanisms. In cancer cells and in some highly proliferative somatic 
tissues, telomeric DNA can be synthesized de novo by the ribonucleoprotein enzyme 
telomerase which adds telomeric repeats to the chromosome ends (Shay et al., 1997). 
Unlike cancer cells, in normal human somatic cells the level of telomerase activity is 
not sufficient to avoid telomere shortening. The negative regulation of telomere ends 
might involve a mechanism called “telomere trimming”, in which the t‐loop structure is 
resolved by resolvases and leads to the formation of a truncated telomere and a 
telomeric circle (Pickett et al., 2011; Palm et al., 2008). Wan and colleagues noticed 
that a mutant deficient in the binding between SLX4 and SLX1 failed to rescue the 
telomere length defect due to SLX4 depletion and further in vitro experiments 
demonstrated that SLX1 is necessary for the cleavage of a D‐loop (a structure that is 
part of the t‐loop). These data led to speculation that the binding of SLX4 at telomeres 
is required to prevent telomere over‐lengthening by recruiting the SLX1 nuclease to 
telomeres. Therefore, SLX4 might act as a negative regulator of telomere length (Wan 
et al., 2013). 
 
 
1.9 Regulation of SLX4 by posttranslational modifications 
Yeast SLX4 is controlled by protein phosphorylation. The Rouse lab reported that after 
DSBs, Slx4 is phosphorylated by the Mec1 and Tel1 kinases (ATR and ATM, 
respectively) on at least six Ser/Thr residues. Mutation of just one of these 
phosphorylation sites (Thr 113) strongly reduced the Slx4‐dependent, Rad1‐Rad10‐ 
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dependent cleavage of non‐homologous DNA tails during single strand annealing 
pathway and gene conversion (Flott et al., 2007; Toh et al., 2010). Moreover, a large‐ 
scale proteomic screen of proteins phosphorylated in response to ionizing radiation, 
found that the murine Slx4 was also phosphorylated on consensus sites recognized by 
ATM and ATR (Ser/Thr – Gln) (Matsuoka et al., 2007). A smaller scale proteomic 
analysis also found a SQ/TQ site on human SLX4 that was phosphorylated after IR 
treatment (Mu et al., 2007). 
 
 
There are no data yet confirming the Slx4 phosphorylation sites from the global 
screens, and there is no information yet on how phosphorylation might affect SLX4 
function in mammalian cells. SLX4 was shown to interact with PLK1, and interesting 
functional connections have been made between Mus81 and Plk1 in budding yeast. 
The yeast orthologue of EME1, Mms4 was shown to bind to and to be phosphorylated 
by Cdc5, the yeast equivalent of PLK1 that is active only during the M phase of the cell‐ 
cycle (Lee et al., 2003; Clyne et al., 2003). Further analysis showed that the Cdc5‐ 
dependent phosphorylation of Mms4 was coincident with an increased activity of 
Mus81‐Mms4 towards HJs (Matos et al., 2011); therefore the activity of the complex 
appears to be tightly regulated during cell cycle. Consistent with the role played by 
Cdc5 in the regulation of Mus81‐Mms4, the human Cdc5‐homologue, PLK1 was shown 
to be involved in the activation of MUS81‐EME1 in G2/M phase in human cells (Matos 
et al.,  2011). PLK1 phosphorylates EME1  and this  modification coincides with  an 
increase in the resolution of HJs. (Wyatt et al., 2013; Matos et al., 2011). However, it is 
not clear if phosphorylation of EME1 in humans is the mechanism whereby PLK1 
increases HJ resolving activity. In budding yeast the Mus81‐Mms4 heterodimer does 
not interact with Slx4 and there is no evidence that Slx4 is phosphorylated by Cdc5. 
31  
Interestingly, in human cells MUS81‐EME1 becomes part of the SLX4 complex and SLX4 
directly interacts with PLK1 (Svendsen et al., 2010). 
 
 
SLX4 might be regulated by post‐translational modifications other than 
phosphorylation, such as sumoylation or ubiquitination. Ubiquitination is the process 
through which a small polypeptide (ubiquitin) is conjugated to an internal lysine in 
target proteins. The conjugation is ATP dependent and involves activating enzymes 
(E1), conjugating enzymes (E2) and ligases (E3) (Kerscer et al., 2006). In the FA pathway 
on which SLX4 functions, ubiquitination is a central mechanism. The FA core complex 
monoubiquitinates the two components of the ID complex (FANCI/FANCD2) (Alpi et al. 
2009; Meetei et al. 2003); the mono‐ubiquitinated form of FANCD2 recruits the FAN1 
nuclease to sites of ICLs by virtue of a UBZ4‐type ubiquitin binding domains in FAN1 
(Garner et al., 2011). Importantly SLX4 also has two UBZ4‐type domains, that when 
mutated cause FA in humans (Stoepker et al., 2011; Kim et al., 2011). Our lab recently 
found that the first of the two tandem UBZ domains in SLX4 recruits SLX4 to DNA 
damage sites independently of FANCD2; therefore the ubiquitinated ligand that 
recruits SLX4 is unknown. 
 
 
My project has involved studying the regulation of human SLX4 by phosphorylation 
and characterizing new factors that might be required for the ubiquitination of the 
SLX4 complex. 
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PROJECTS: 
 
PROJECT 1: Identification of sites of SLX4 phosphorylation in vivo. 
PROJECT 2: Identification of novel SLX4‐interacting proteins. 
PROJECT 3: Does SLX4 interact with MSH2‐MSH3? 
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2 MATERIALS AND METHODS 
 
 
2.1 Materials 
 
 
 
2.1.1 Buffers and solutions 
 
Lysis Buffer 
 
Reagent Final concentration 
TRIS HCl (pH 7.4) 50 mM 
NaCl 150 mM 
EDTA (pH 8) 1 mM 
EGTA (pH 8) 1 mM 
Triton X‐100 1% 
Sucrose 270 mM 
Β‐Mercaptoethanol 10 μl in 10 ml of final buffer volume 
Protease inhibitor 1 tab 
Phosphatase inhibitor 1X 
Benzonase 0.2% 
 
 
RIPA buffer 
 
Reagent Final concentration 
TRIS HCl (pH 7.5) 50mM 
NaCl 150 mM 
NP‐40 1% (v/v) 
DOC 1% (v/v) 
SDS 0.1% (v/v) 
EDTA 2 mM 
Protease inhibitor 1X 
Phosphatase inhibitor 1X 
Benzonase 0.2% 
 
 
Tris Buffer Saline (TBS) 
 
Reagent Final concentration 
TRIS HCl (pH 7.5) 50 mM 
NaCl 150 mM 
DOC 1% (v/v) 
TBS‐Tween 
Tween 20 0.1% (v/v) 
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10X TG buffer 
 
Reagent Final concentration 
TRIS base 30 g 
Glycine 144 g 
Sterile water Up to 1l 
 
 
1X Transfer buffer 
 
Reagent Final concentration 
10x TG buffer 100 ml 
Methanol 200 ml 
Sterile water Up to 1l 
 
 
10X TE buffer (pH8) 
 
Reagent Final concentration 
TRIS HCl (pH 8) 100 mM 
EDTA 10 mM 
Autoclave 
 
 
10X LiAc 
 
Reagent Final concentration 
Litium Acetate 1M 
Filter sterilize 
 
 
1X LiAc/40%PEG‐3350/0.5X TE 
 
Reagent Final quantity 
10X LiAc 10 ml 
10X TE 5 ml 
PEG‐3350 40 g 
Sterile water Up to 10 ml 
Filter sterilize 
 
 
Z buffer 
 
Reagent Final quantity 
Na2HPO4 x 7H2O 16.1 g 
Na2HPO4 x H2O 5.5 g 
KCl 0.75 g 
MgSO4 x 7H2O 0.246 g 
Sterile water Up to 1000 ml 
Adjust pH to 7 and sterilize 
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Staining buffer for FACS experiments 
 
Reagent Final concentration 
Propidium iodide 50μg/ml 
Ribonuclease A 50μg/ml 
triton X‐100 in PBS 0.1% v/v 
 
 
2.1.2 Kits 
 
 
Kit Source Catalogue number 
QIAquick gel extraction QIAGEN 28704 
QIAprep Spin Miniprep QIAGEN 27106 
QIAprep Spin Maxiprep QIAGEN 12663 
 
 
2.1.3 Media 
 
Liquid media and agar plates for yeast and bacteria culture were prepared by the 
Kitchen Service, University of Dundee. 
Luria Bertani (LB) broth 
 
Reagent Final concentration 
Tryptone 1% 
Yeast extract 0.5% 
Sodium chloride 1% 
 
 
When needed Ampicillin was added to a final concentration of 50 μg/ml (LB/Amp). 
LB/Amp plates contained additional 2% (w/v) bacto‐agar, and were stored at 4°C 
YPAD 
 
Reagent Final concentration 
Yeast extract 1% 
Peptone 2% 
Glucose 2% 
AGAR 2% 
Adenine 0.01% 
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Synthetic Dextrose minimal media (SD) 
 
Reagent Final concentration 
Yeast nitrogen base without aminoacids 0.67% 
Dextrose 2% 
 
 
Amminoacids and bases were supplemented as required: 0.08% (w/v) each of adenine, 
uracil, tryptophan, histidine, arginine, and methionine; 0.12% (w/v) each of tyrosine, 
and lysine; 0.24% (w/v) leucine; 0.2% (w/v) phenylalanine; 0.8% (w/v) threonine). SD‐ 
plates contained additional 2% (w/v) bacto‐agar. 
SOC medium 
 
Reagent Final concentration 
Yeast extract 0.5% (w/v) 
Tryptone 2% (w/v) 
Glucose 20 mM 
KCl 2.5 mM 
MgCl2 10 mM 
NaCl 10 mM 
 
 
2.1.4 Antibodies 
 
Antibodies against human SLX4 and human SLX1 were generated and supplied by DSTT 
(Division of Signal Transduction Therapy) at the Dundee University. The sequence of 
target proteins were fused to GST and expressed in bacteria and then used as antigens 
for injection into sheep. All secondary antibodies purchased were horseradish 
peroxidise (HP) conjugated. 
 
Primary antibodies Source Catalogue 
number 
CUL1 Invitrogen 71‐8700 
FBXO11 Bethyl A301‐177A 
GAPDH Abcam Ab8245 
MSH2 Bethyl A300‐452A 
MSH3 Santa Cruz SC‐271080 
MUS81 ImmuQuest IQ285 
RBX1 Abcam Ab2977 
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SKP1 Santa Cruz SC‐5281 
SLX1 DSTT* S701C 
SLX4‐C DSTT* S714C 
XPF ThermoScientific Ab‐1 (clone 219) 
UBR5 Bethyl A303‐045A 
Secondary antibodies   
Mouse IgG (H + L) (HRP) Pierce 31430 
Rabbit IgG (H + L) (HRP) Pierce 31460 
Sheep IgG (H + L) (HRP) Pierce 31480 
*Cloning team, University of Dundee 
 
2.1.5 Plasmids 
 
 
Name Source Catalog number 
MSH2 DSTT* 19058 
MSH3 DSTT* 19059 
SLX4 DSTT* 16417 
pDONOR Life technology 11798‐014 
pDEST22 Life technology ‐ 
pDEST33 Life technology ‐ 
*Cloning team, University of Dundee 
 
 
 
2.1.6 Small interfering (si)RNA oligos 
 
UBR5 siRNAs duplexes were purchased from Eurofins‐MWG. 
 
Target Oligo number Target sequence (sense) 
UBR5 1 GCA CUU AUA UAC UGG AUU A 
UBR5 2 GAU UGU AGG UUA CUU AGA A 
UBR5 3 GGU CGA AGA UGU GCU ACU A 
 
 
2.1.7 Oligonucleotides 
 
All the oligonucleotides listed below are flanked with attB oligos for Yeast Two Hybrid 
analysis, and they were synthesized by the Oligonucleotide Synthesis Service, 
University of Dundee. 
MSH2 
 
Fwd_attB1_MSH2: 5’ ‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG GCG GTG CAG 
CCG AAG – 3’ 
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Rev_attB2_MSH2: 5’ ‐ AC CAC TTT GTA CAA GAA AGC TGG GTT CGT AGT AAC TTT TAT 
TCG TGA AAT GAT TTC – 3’ 
 
 
 
MSH3 
 
Fwd_attB1_MSH3: 5’ ‐ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG TCT CGC CGG 
AAG CCT GC‐3’ 
Rev_attB2_MSH3: 5’ ‐ AC CAC TTT GTA CAA GAA AGC TGG GTT ATG AAG AAG AGA 
AGT CTG TGT TTC TTC CAT GTT G – 3’ 
SLX4 
 
Fwd_attB1_SLX4: 5’‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG AAA CTG AGT GTG 
AAT GAG GCT CAG CTA GGC ‐ 3’ 
Rev_attB2_SLX4: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT GTT CCG CTC CAC CTT 
CTT CTT GCC CCG AGG CTG ‐ 3’ 
Fwd_attB1_SLX4‐X2/X4: 5’‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG GAG GTT 
GGC CCC CAG CTC CTG CTT CAG GCT ‐ 3’ 
Rev_attB2_SLX4‐X1: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT GTT CAA GGT TCG 
GCC GCC CCT GTC CGG GTG CTT ‐ 3’ 
Rev‐attB2_SLX4‐X2: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT GTT GGC AAT AGG 
CAC CTG TTC 
GCA CAG GTG AAC ‐ 3’ 
 
Rev‐attB2_SLX4‐X3/X4: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT CAA GGT TCG GCC 
GCC CCT GTC CGG CTC CTT GTC ‐ 3’ 
Fwd_attB1_SLX4‐M1: 5’‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG ACT GAC TCA 
GAG GGC AAA CCA TGG GAG GAG ‐ 3’ 
Fwd_attB1_SLX4‐M2: 5’‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG CTC TCC CTC 
GGG CTG CTG GTT GCT GAC TTT GG ‐ 3’ 
Rev_attB2_SLX4‐M: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT GTT CAT CGG CGT TAT 
GGG CAC TTT GGG GGG CAA ‐ 3’ 
Fwd_attB1_SLX4‐S: 5’‐ ACA AGT TTG TAC AAA AAA GCA GGC TTC ATG CAG ACC TAC 
AAG CCT TCA AGG GCA GGG GTC ‐ 3’ 
Rev_attB2_SLX4‐S: 5’‐ AC CAC TTT GTA CAA GAA AGC TGG GTT GTT CCG CTC CAC CTT 
CTT CTT GCC CCG AGG CTG ‐ 3’ 
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2.1.8 Yeast and bacterial strains 
 
 
Name Organism Source Catalog number 
MAV203 S. cerevisiae Life technology 11281‐011 
TOP10 E. coli Invitrogen C4040‐10 
DH5α E. coli DSTT ‐ 
 
 
 
2.2   Methods 
 
 
 
2.2.1 Determination of protein concentration 
 
Protein concentrations were measured by the Bradford method (Bradford 1976). A 
standard curve was prepared according to the manufacturer’s protocol, by adding 
increasing amount of BSA to a final volume of 0.1 ml with water, and then mixing with 
0.9 ml Bradford reagent. The mixture was allowed to stand at room temperature for 5 
min. The optical density of the standards was measured at 595 nm (OD595) in 1.5 ml 
plastic cuvettes against a reference cuvette containing water (0.1 ml) and Bradford 
reagent (0.9 ml). This was used to construct a standard curve that was employed to 
determine protein concentrations of cell lysates. On average the linear range of 
protein Bradford measurements lies between OD595 0.1 and OD595 0.7. Cell lysates were 
diluted so that the OD595 lay in this range. Bradford measurements were performed in 
triplicate. 
 
 
2.2.2 Determination of DNA concentration 
 
The absorbance of DNA in aqueous solutions was measured in a disposable UVette at 
260 nm with a Biophotometer, using the OD260 of sterile water as zero. 
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2.2.3 DNA sequencing 
 
Sequencing of either plasmid DNA or PCR product DNA was performed by The 
Sequencing Service, School of Life Science, University of Dundee, using DYEnamic ET 
terminator chemistry (Amersham Pharmacia Biotech) on Applied Biosystems 
automated DNA sequencers. For DNA containing high GC content (typically > 75%), 
10% (v/v) of GC‐melt solution (Clontech) was added to the sequencing reaction. 
 
 
2.2.4 Immunoprecipitation (IP) 
 
 
 
2.2.4.1 Conjugation of antibodies to protein‐G Sepharose 
 
The required volume of protein‐G Sepharose was washed 3 times in PBS then adjusted 
to a 50% (v/v) slurry in PBS before addition of antibodies. The antibody/Sepharose 
mixture was mixed on a platform shaker at 4°C. After 60 min, the beads were washed 3 
times with PBS. Generally, 2 μg of antibody was conjugated to 10 μl of settled protein‐ 
G Sepharose beads. 
 
 
2.2.4.2 Immunoprecipitation of proteins from native cell lysates 
 
Generally 2μg coupled antibody was used per 1 to 3 mg extract. The antibody‐bead 
conjugate was incubated with cell extract for 2 hours at 4 °C on a shaking platform or a 
roller depending on the size of the tube used. The supernatant was removed and the 
beads washed three times with 500μl of lysis buffer and a final wash was done with 
500μl of Tris HCl (50mM) and 270 mM of Sucrose. Immunoprecipitates were 
denatured in lithium dodecyl sulphate (LDS) sample buffer (1x) and β‐mercaptoethanol 
(5%   v/v).   Samples   were   boiled   at   95°C   for   5‐10   min   before   loading   onto 
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polyacrylammide gels. 
 
 
 
 
2.2.5 Separations of proteins by sodium dodecyl sulphate (SDS)‐ 
polyacrylammide gel 
Two SDS‐PAGE systems were used in this thesis depending on the experiment. The first 
one was NuPAGE 4‐12% Bis‐Tris pre‐cast gels coupled with the BioRad system for 
electrophoresis transfer. Electrophoresis was performed using electrophoresis buffer 
at constant voltage of 150V for 90 to 105 min, depending on the experiment. 
Invitrogen Bis‐Tris gels were run in Novex NuPAGE 3‐[N‐morpholino] propane 
sulphonic acid (MOPS) running buffer. 
The second system used was the ATTO self‐pour gel system for gel electrophoresis 
coupled with the BioRad system for electrophoretic transfer. Slab gels for the ATTO 
system were poured between glass plates using separating gel consisting of 0.375M 
Tris‐HCl pH 8.8, 0.1% (w/v) SDS, 10% (w/v) acrylammide/o.4% (w/v) N,N’‐methylene 
bisacrylammide and 0.075% (w/v) ammonium persulphate. Polymerisation was 
initiated by the addition of 0.1% (v/v) tetramethylethylenediamide (TEMED). 
Isopropanol was then layered carefully over the acrylamide solution and 
polymerisation allowed to continue for at least 15 min. The isopropanol was removed 
and stacking gel comprising 0.125M Tris‐HCl (pH 6.), 0.1% (w/v) SDS, 3% (W/v) 
acrylamide/0.08% (w/v) N, N’‐methylene bisacrylamide, 0.075% (w/v) ammonium 
persulphate and 0.1% (v/v) TEMED, was poured onto the seprarating gel top and a 14‐ 
well comb was added prior to polymerisation and left to set for at least 10 min. 
Electrophoresis was performed using electrophoresis buffer at a constant voltage of 
150V for 90 min. 
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2.2.6 Staining of protein gels 
 
To visualize proteins after SDS‐PAGE, gels were stained Colloidal Coomassie Blue 
staining solution for 60 to O/N at room temperature with a continual agitation on a 
rocking platform. Gels were destained with water, using several changes until the 
background staining was greatly reduced. 
 
 
2.2.7 Western blotting 
 
Protein gels were assembled into a gel‐membrane sandwich as described in the 
manufacturer’s protocol. Nitrocellulose membrane was placed on a gel, this assembly 
was posed between two sponges. All components were pre‐soaked in transfer buffer. 
This assembly was loaded into a BioRad Mini‐Cell tank filled with transfer buffer, and 
proteins were transferred to nitrocellulose at 105V for 105 min. The nitrocellulose 
membrane was blocked in TBS‐Tween 0.15% containing either skimmed milk (5% w/v) 
or BSA (4% w/v) for 1 h at room temperature. Primary antibodies were diluted in TBS‐ 
Tween containing either skimmed milk (5% w/v) or BSA (4% w/v) and, depending on 
the efficiency of the antibody, incubated for 1‐2h at room temperature or 4°C O/N. 
The membrane was washed 3 times for 10 min each with TBS‐Tween 0.15%, incubated 
with secondary antibodies conjugated to horseradish peroxidase (HP) (all secondary 
antibodies were used at 1:5000 dilutions in TBS‐T containing either skimmed milk (5% 
w/v) or BSA (4% w/v)) for 1h at room temperature. After the three round of washing, 
the membrane was developed with enhanced chemiluminescence reagent (ECL). To 
detect secondary antibodies conjugated with HP, ECL reagents 1 and 2 were mixed in 
equal volumes and 1 ml of this mix was added to each blot for 1min. The membrane 
was  then  placed  in  a  clean  piece  of  polythene  roll  in  an  autorad  cassette.  The 
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membrane was then exposed to Medical X‐Ray Film (Konica Minolta) and developed in 
an automatic processor. 
 
 
2.2.8 In gel digestion of proteins for Mass spectrometric analysis 
 
To minimise keratin and other exogenous contaminations, all manipulations of gels for 
mass spectrometry analysis were prepared under a laminar flow hood. Protein bands 
were excised from a colloidal Coomassie stained gel, using a sterile scalpel. Gel pieces 
were washed with 0.5 ml each of 50% acetonitrile/water 0.1 M NH4HCO3 and 50% 
Acetonitrile/50 mM NH4HCO3. All washes were performed on a Vibrax shaking platform 
for 10 min. All liquid was removed between washes. Proteins were then reduced with 
0 mM DTT in 0.1 M NH4HCO3 (45 min, 65°C) and alkylated with 50 mM iodoacetamide 
in 0.1 M NH4HCO3 (30 min at room temperature). Gel pieces were then repeatedly 
washed with 0.1 M NH4HCO3 and 50% Acetonitrile/50 mM NH4HCO3. Once colourless, 
the gel pieces were shunk with 0.3 ml acetonitrile for 15 min, the acetonitrile was then 
removed and a Speed‐Vac was used to dry the gel pieces. The latter were then swollen 
in 25 mM Triethylammonium bicarbonate with 5 μg/ml of trypsin and incubated over‐ 
night at 30°C on a shaker. After 12 h an equivalent volume of acetonitrile was added to 
the digest and incubated for further 15 min. The supernatants were transferred to a 
clean tube and concentrated to dryness by Speed Vac. Meanwhile 100 μl 50% 
acetonitrile/25% formic acid was added to the gel pieces. This second extraction was 
combined with the dried first extract. The samples were then stored at 20°C. 
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2.2.9 Mass spectrometry 
 
Liquid chromatography‐mass spectrometry (LC‐MS) analysis was performed by Dr. 
David Campbell and Dr. Robert Gourlay. The reconstituted tryptic peptides were 
injected onto a Dinex 3000 nano liquid chromatography system coupled to a Thermo‐ 
Electron LTQ‐orbitrap mass spectrometer. Data files (raw files) were converted to 
MSM files which were then submitted to the in house Mascot server. Peptide mass 
fingerprinting analysis was performed using OLMAT 
(http://www.proteinguru.com/MassSpec/OLMAT). 
 
 
 
2.2.10 Cell cycle analysis 
 
 
 
2.2.10.1 Elutriation of NB4 cells 
 
This protocol was used to enrich for cells at G1, S, and G2/M cell cycle phases by 
centrifugal elutriation. 
Preparing the elutriator 
 
 
With a high flow of elutriation buffer, i.e. Flow Setting (FS) of ~150, all air bubbles were 
ejected from tubing by squeezing and releasing the tubing at ~10 psi of backpressure. 
Bubbles were then removed from chamber by repeating the same procedure with the 
chamber held upright. Fow was turned off. The Trap Valve was turned to Pos 1 and the 
Inject Valve to Pos 1. To  remove bubbles trapped in  the elutriation chamber the 
centrifuge spin was set at 1000 rpm. Centrifuge and flow rate were then stopped. 
Elutriation 
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Cells were pelleted (1000 rpm, 4 min), resuspended in 5 mL elutriation buffer and 
transferred to 50 mL falcon tube. They were then loaded into syringe and pass slowly 
through 18 gauge needle into same falcon tube to produce monodispersion. This was 
repeated three times. 
Next the centrifuge was set at 1800 rpm and FS to 102. If the back pressure increased 
above 5 psi, centrifuge was stopped, and tubes repositioned. 
Cells were loaded into syringe, leaving a small aliquot in 50 mL tube for asynchronous 
control. 
Next bubble trap was removed from flow (Trap Valve Pos 1) and the syringe inserted 
into luer lock. The Inject Valve was turned so that the bubble trap is isolated (Inject 
Valve Pos 2) and only after that, cells were slowly injected into the bubble trap. The 
Inject Valve was then closed (Inject Valve Pos 1) and the bubble trap reconnected to 
the flow (Trap Valve Pos 2). Flow was adjusted to ensure that cells filled the chamber. 
After all cells were loaded into the chamber, Trap Valve was switched to Pos 1. For 
each fraction, cells were collected into 50 mL falcon tube. For NB4 cells, FS was: 112 
(G1), 118, 122 (S), 126, 130, and 150 (G2/M). Spin was then stopped, and the last 50 
mL fraction (“Post”) collected. Elutriation buffer was replaced with 70% ethanol to 
clean the tube and let it flow until all liquid was removed. 
Notes 
 
 
 Trap Valve 
 
o Pos 1: The T‐valve is turned such that the flow goes through the bubble 
trap 
o Pos 2: Bypass the bubble trap 
 
 Inject Valve 
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o Pos 1: The “OFF” end is pointing towards the luer lock. 
 
o Pos  2:  The  “OFF”  end  is  pointing  towards  the  T  junction  with  the 
peristaltic pump. 
 
 
 
2.2.10.2 Cell cycle analysis by FACS: Propidium Iodine stained cells  
This protocol has been used to stain DNA deriving from cells collected during time 
points  in  cell‐cycle  experiments.  The  pellet  deriving  from  cells  collected  during 
timepoints, was resuspended  in 1 ml of 70% of cold ethanol and left at least for 30 
min at room temperature. Cells were washed twice in PBS + 1% BSA or FCS (Fetal Calf 
Serum) and filtered through filcons 50 μm, BD (Biosciences) in FACS tubes to get rid of 
clumps of cells. Cell were then pelleted and resuspended in 1 ml of staining buffer, 
incubated at room temperature protected from light for at least 20 min, and analyzed 
by flow cytometry. Live cells were gated on the flow cytometer using forward scatter 
and side scatter parameters. DNA was detected in the FL2‐H channel. FL2‐W and FL2‐A 
were used to distinguish single cells. Cell numbers at different cell‐cycle stages were 
measured on FlowJo. 
 
 
2.2.11 Yeast two hybrid assay (Gateway cloning) 
 
 
 
2.2.11.1 attB flanked PCR amplifications of the fragments 
 
 
 
 
REAGENTS QUANTITY (final concentration) 
Platinum SuperMix HiFi 45 μl 
Template 10 ng 
Primers flanked by attB sites 1 μM 
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TEMPERATURE TIME 
94°C 2 min 
94°C 30 sec 
55°C 30 sec 
68°C 3 min 
68°C 10 min 
6°C O/N 
 
 
 
 
 
 
25 cycles 
 
 
 
 
 
 
 
The PCR products were then run into an agarose gel electrophoresis and bands 
visualized under UV light. Gel pieces at the correct molecular weight were cut, inserted 
into a 15 ml falcon tube, and DNA was extracted from the agarose by using a QIAquick 
Gel Extraction Protocol. The concentrations of the fragments were checked on a 
Nanodrop. 
 
 
2.2.11.2 BP reaction 
 
attB flanked PCR products were introduced into an expression vector (pDONOR) in a 
reaction mediated by BP clonase enzyme, this yielded to a pENTR vector containing the 
fragments of interest. The pDONOR carried a spectinomycin resistance gene for further 
selection in E. coli. 
REAGENTS QUANTITY (final concentration) 
pDONOR 150 ng 
attB flanked PCR 100 ng 
TE buffer pH8 up to 10 μl 
BP clonase enzyme 2 μl 
 
 
The  reaction  was  mixed  by  vortex,  and  incubated  at  25°C  for  20h.  Next,  1μl  of 
proteinase K solution was added, and incubated at 37°C for 10min. 
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2.2.11.3 Transformation of pENTR into TOP10 E.coli strain 
 
A maximum  of 2.5 μl  of the  BP recombination reaction  was added into  a chilled 
electroporation cuvette , next 100 μl of TOP10 cells were added and gently mixed. 
Cells were electroporated by choosing EC2 (bacteria) program + pulse once. For the 
recovery of the cells, 500 μl of SOC medium was added into the mix, pipetted gently 
and transferred into a 1.5ml eppendorf tube. Cells were incubated at 37°C for 30 min 
in a thermomixer and finally plated on a LB + spectinomycin plate (to select positive 
clones) and incubated at 37°C O/N. 
The day after, each colony was inoculated in 3 ml LB + spectinomycin medium and 
incubated at 37°C O/N. DNA was purified by using a QIAprep Spin Miniprep kit and the 
correct sequence of the constructs was verified by restriction enzymes and sequence 
analysis. 
 
 
2.2.11.4 LR reaction 
 
pENTR vector was recombined with a destination vector (pDEST) to create an 
expression clone containing fragments of interest. pDEST22 is the GAL4 Activation 
Domain, and pDEST32 is the GAL4 DNA Binding Domain containing destination vector. 
pDEST22 encodes ampicillin resistance, whereas pDEST32 carries a gentamycin 
resistance gene for further selection in E. coli. 
REAGENTS QUANTITY (final concentration) 
pENTR 150 ng 
pDEST32/22 150 ng 
TE buffer pH8 up to 10 μl 
LR clonase enzyme 2 μl 
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The  reaction  was  incubated  at  25°C  for  1/2hours,  transformed  into  TOP10  and 
subsequently plated onto gentamicin plates (10μg/ml). 
 
 
2.2.11.5 Transformation of pDEST22 and pDEST32 into MAV203 cells  
A colony of MAV203 was inoculated in 10 ml of YPD and incubated overnight at 30°C. 
The next day the OD600 of the culture was determined and cells were diluted to an 
OD600 of 0.4 in 50ml of YPD and let them grow additional 2‐4 hours. Cells were then 
pelleted at 2500 rpm and resuspended in 40ml 1X TE; pelleted a second time at 2500 
rpm and resuspended in 2ml of 1X LiAc/0.5X TE. 
Finally cells were incubated at room temperature for 10 minutes. 
 
For each transformation 1 μg of plasmid DNA and 100 μg of denatured sheared salmon 
sperm DNA was mixed together with 100 μl of the yeast suspension. Next, 700 μl of 1X 
LiAc/40% PEG‐3350/1X TE was added to the cells and mixed well. The solution was 
incubated at 30°C for 30 minutes. After that, 88 μl of DMSO was added, mixed well, 
and cells were subjected to heat shock at 42°C for 7 minutes. Cells were then 
centrifuged for 10 seconds, the supernatant removed, and the pellet resuspended in 1 
ml 1X TE and re‐pelleted. After removing the supernatant from the second 
centrifugation, the pellet was resuspended in 50/100 μl TE and plated on –LEU, ‐TRP 
plates to select the insertion of both of pDEST plasmids. Single colonies were picked 
and a drop test performed on –LEU, ‐TRP plates. After that, cells were replica plated on 
YPAD containing a nitrocellulose membrane for the X‐gal assay, –LEU, ‐TRP, +HIS 
plates to test for the activation of HIS3 reporter gene. 
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2.2.11.6 X‐gal assay 
 
For each membrane, 10 mg X‐gal was dissoved in 100 μl N,N‐dimethyl formamide 
(DMF). The solution was combined with 60 μl β‐mercaptoethanol and 10 ml Z‐buffer. 
Two round 125‐mm Whatman 541 filter papers were stuck in a 15 cm petri dish, and 
saturated with 8ml of the X‐gal solution. Any air bubbles were removed. Using forceps, 
the membrane  was removed  from the  surface of  the YPAD  plate and  completely 
immersed in liquid nitrogene for 20‐30 seconds. The frozen membrane was placed on 
top of the soaked Whatman filters colony side up. Any air bubbles and excess buffer 
were removed. Plates were then covered and incubated at 37°C up to 24 hours. 
 
 
2.2.12 Transformation of Escherichia coli cells (DH5α ) 
 
For each transformation, competent E. Coli cells (50 μl) from 80°C glycerol stocks were 
thawed on ice. Plasmid DNA (around 50 ng) was added to the cells, mixed gently, and 
incubated on ice for 5‐20 min. To facilitate the uptake of DNA, cells were heat‐shocked 
with an incubation at 42°C for 30s, then the cells were placed back on ice for further 2 
min. Plasmids requiring ampicillin selection were streaked directly onto LB/Amp agar 
plates. For plasmids requiring any other selection, LB (1 ml) was added to the cells and 
the cells were allowed to recover at 37°C for 1 h in a shaking incubator, before being 
plated onto LB agar plates. Cells were let growing on the plates O/N at 37°C. 
 
 
2.2.13 Preparation of plasmids from bacteria 
 
To prepare small amounts of plasmid DNA in microgram quantities (termed ‘mini‐ 
prep’), DH5α E. coli cells were transformed with plasmid DNA, and a single colony was 
inoculated in LB/Amp (5 ml). The transformed cells were grown in LB media containing 
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appropriate antibiotics to stationary phase by incubation at 37 °C overnight in a 
shaking incubator. After centrifugation in an AllegraTM6R bench‐top centrifuge 
(Beckman), plasmid DNA was extracted from the cell pellet by sequential lysis, 
precipitation, binding to Qiagen anion exchange column and elution on an automated 
Qiagen BioRobot 9600 using the QIAsoft 3.0 software program, by the DNA Sequencing 
Service (University of Dundee). The DNA was eluted in sterile water (100 μl) and 
typically yielded 100‐300 μg/ml plasmid DNA. 
To prepare larger quantities of plasmid DNA, ‘maxi‐preps’ were performed using the 
Qiagen DNA Maxi Kit. A single bacterial colony, transformed with the relevant 
construct, was used to inoculate LB (250 ml) containing the appropriate antibiotic. 
After an overnight incubation at 37 °C, the cells were pelleted by centrifugation at 
3,000 rpm for 10 min in a J‐6 Beckman centrifuge. Plasmid DNA was purified according 
to the manufacturer’s instructions. Overnight cultures of 250 ml typically yielded 0.5‐1 
mg plasmid DNA. 
 
 
2.2.14 Restriction digests of DNA 
 
Restriction digests were performed at 37 °C for 1‐2 hours. Restriction enzymes were 
used according to the manufacturer’s protocol. Typically, 100 ng of DNA was digested 
with the relevant restriction enzyme buffer, water, BSA (at final concentration of 100 
μg/ml) and restriction enzyme (generally 1 unit of enzyme per 1 μg of DNA). 
 
 
2.2.15 Mammalian cell culture 
 
All media and buffers used for mammalian cell culture were pre‐warmed to 37°C prior 
to use and all procedures were carried out under aseptic conditions compliant with 
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biological safety Category‐2 regulations. Unless otherwise indicated, cells were 
cultured and maintained at 37oC in a 5 % CO2 water‐saturated incubator. Cells were 
grown until 80‐90 % confluency before splitting for routine maintenance. 
 
 
2.2.16 Human embryonic kidney 293 (HEK293) cells 
 
HEK293 cells were purchased from the European Collection of Cell Cultures (Salisbury). 
They were cultured in 150 cm2 flasks (for routine passaging) or on 10 cm2 plates in 
DMEM supplemented with 10 % (v/v) fetal bovine serum (FBS) and 1 % (v/v) 
penicillin/streptomycin stock solution (10,000 units penicillin and 10 mg streptomycin 
per ml). For passaging of cells, culture medium was aspirated, cells were washed once 
with sterile Dulbecco’s phosphate buffered saline (PBS) and 2 ml of sterile 
trypsin/EDTA was added per flask. After the cells detached from the surface of the 
flask, they were resuspended to a final volume of 10 ml in complete medium and 
clumps of cells were broken up by passing though a narrow‐ bore pipette several 
times. 2 ml of this cell suspension was used to seed a 150 cm2 flask to maintain stocks 
in 20 ml of complete medium. 
 
 
2.2.17 Cell freezer stocks 
 
Cell stocks were stored at ‐196 °C in liquid nitrogen; when necessary, growing cells 
were frozen down to ensure a constant supply. Cells to be frozen for storage were 
allowed to grow to 80% confluence; after washing with PBS, trypsin was added to 
detach cells. Harvested cells were then washed, to remove trypsin, in an excess of 
normal growth media by centrifugation at 1000 rpm for 5 min. The supernatant was 
removed and after tapping the tube to loosen up the pellet, cells were resuspended in 
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cryogenic storage media (50 % FCS, 10 % DMSO, 40 % DMEM). Cells were resuspended 
so that 1 ml cryogenic storage media contained the same number of cells that would 
have been passaged into a new dish. Aliquots of cell suspension (1 ml) were stored in 
1.5 ml cryogenic screw top vials (Corning) at ‐80°C in an insulated box for 24 h, before 
transfer to the liquid nitrogen cell freezer. This is because, to ensure viability during 
storage at ‐ 196°C, cells must be allowed to cool at a rate slow enough to allow the 
cells time to dehydrate but fast enough to prevent excessive dehydration damage. A 
cooling rate of ‐1°C to ‐3 °C per minute is satisfactory for most animal cell cultures. 
 
 
2.1.9 Transfection of HEK293 with siRNA 
 
siRNAs were dissolved in 5X siRNA buffer (Dharmacon) and made up with water free 
from RNase and DNase according to manufacturers instructions. For a single 
transfection experiment in a 10 cm2 plate, confluent HEK293 cells were trypsinized and 
approximately 4x106 cells were seeded onto a 10 cm2 plate. The cells were allowed to 
 
adhere to the plates and recover from the trypsinization process for 24 h before 
transfection. For each 10 cm2 plate, 50 μl of Hiperfect transfection reagent was mixed 
with proper amount of siRNA (usually from 5 up to 100nM) in a 1.5 ml autoclaved 
eppendorf tube and the mix was added to 500 μl of Dulbecco’s medium. The tube was 
then vortexed and the solution incubated for 10 minutes at room temperature. After 
that the mix was evenly added into the plate and cells were incubated at 37°C. After 
24h the medium was changed with fresh Dulbecco’s medium + FBS, pen/strep, L‐ 
glutammine. 
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2.1.10 Cell treatment with genotoxins 
 
Cells were treated with a variety of genotoxins at a range of concentrations as 
indicated. Cisplatin and camptothecin were dissolved in DMSO to make 1 M stock 
solutions, hydroxyurea was dissolved in Milli‐Q water to make 1 M stock solutions, and 
mitomycin‐C was dissolved in Milli‐Q water to make a 0.5 mg/ml stock solution. All the 
solutions were stored at ‐20°C. Ionising radiation was delivered using a 137Cs radiation 
source at a delivery rate of 3 Gy/min.
56  
3 IDENTIFICATION OF SITES OF PHOSPHORYLATION IN 
HUMAN SLX4 
 
 
3.1 INTRODUCTION 
 
At the outset of this work, there was some limited evidence from proteomic screens to 
suggest that the human and mouse orthologues of SLX4 are phosphorylated on S/T‐Q 
sites, the consensus for ATM/ATR (Flott et al. 2007; Toh et al. 2010; Matsuoka et al. 
2007; Mu et al. 2007), in response to DNA damage. Moreover, the Rouse lab identified 
several S/T‐Q sites of phosphorylation in yeast SLX4 (Flott et al. 2007; Toh et al. 2010). 
All the sites are listed in Table 2. 
 
 
 
Table 2: Previously reported sites of phosphorylation in Slx4. 
 
 
 
 
As mentioned in the Introduction, in budding yeast the phosphorylation of SLX4 is very 
important for the modulation of its activity in single strand annealing (Flott et al. 
2007). This function could have been conserved through the evolution and other 
phosphorylation‐dependent functions could have arisen. Therefore, I performed an 
analysis to find the key residues on human SLX4 that are phosphorylated in vivo, and to 
understand their impact on the SLX4 activity. For my project I used an approach 
57  
that combined an immunoprecipitation of the endogenous SLX4 with 
phospho‐mapping analysis of the protein sequence by mass‐spectrometry. 
 
 
3.2 RESULTS 
 
3.2.1 Optimization of SLX4 yield prior to immunoprecipitation 
 
In order to find the optimal conditions to immunoprecipitate (IP) SLX4, I first lysed 
different human cell lines (Table 3) and checked the expression levels of SLX4 by 
western blot (Fig.5). 
SLX4 was most abundant in HEK293, Ramos, and U2OS cells. I decided to choose 
HEK293 cells to go forward. It is important to underline that all cell lines expressed 
SLX4 (data not shown), but in some of cell lines shown in Fig. 1, the abundance of the 
protein was low that SLX4 was not detectable at the low exposures necessary to avoid 
overexposure of the stronger signals. 
 
 
I next aimed to map SLX4 phosphorylation sites before and after exposure of cells to 
agents that induce DNA damage. I first optimized the extraction of SLX4 during cell 
lysis to ensure that I could immunoprecipitate as much of the total SLX4 as possible. I 
first determined which lysis conditions would yield high levels of soluble SLX4. In Fig.5 
lysis buffer contained only 150mM NaCl and not all the protein became soluble (data 
not shown), suggesting that a fraction of SLX4 was still bound to the chromatin. 
Therefore, I tried supplementing the buffer with increasing concentrations of  salt 
(NaCl) with or without addition of benzonase, a genetically engineered endonuclease 
that degrades both DNA and RNA. As shown in Fig.6, the amount of protein in the 
pellet diminished with increasing salt concentrations; moreover, the benzonase did not 
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seem to affect the release of the protein. Hence, supplementing the lysis buffer with 
300mM NaCl ‐ without benzonase ‐ gave the best conditions to release SLX4 from the 
chromatin pellet. I used these lysis conditions to immunoprecipitate SLX4 from HEK293 
cells in subsequent experiments. 
 
 
 
Table 3: List and origin of human cell lines used to test expression of SLX4. 
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HEK 293 
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Figure 5: Expression levels of SXL4 across a panel of cell lines listed in Table1. 
 
Western blot analysis of SLX4 expression in the cell lines listed in Table 1. Cells were lysed in 
buffer containing 150 mM. GAPDH was used as loading control.  Supernatant  shown.  Red 
arrows highlight the three cell lines that expressed the highest levels of SLX4  which  are 
HEK293, U2OS and RAMOS cells. 
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Figure 6: Testing different lysis conditions for SLX4 extraction from HEK293 cells. 
 
HEK293 cells were lysed in lysis buffer with the supplements indicated. “Sup” denotes 
supernatant from centrifugation of lysates, pellet denotes the pellet remaining after 
centrifugation. 
61  
3.2.2 Large scale immunoprecipitation and phospho‐site mapping of 
SLX4 
It is known that human SLX4 is involved in the repair of DNA interstrand crosslinks 
(ICLs), and cells defective in SLX4 are hypersensitive to agents that induce ICLs. 
Therefore I compared phospho‐sites of endogenous human SLX4 before and after 
treating cells with the DNA crosslinking agent mitomycin C (MMC) via 
immunoprecipitation and mass spectrometry analysis. MMC induces the activation of 
the DNA damage response (DDR), which is orchestrated by the activity of 
phosphoinositide 3‐kinase related kinases (PIKKs) ATM and ATR (Cimprich and Cortez 
2008), which have been reported to target murine and yeast Slx4 (Flott et al. 2007; Toh 
et al.  2010; Matsuoka et  al. 2007). For cell  lysis, I used  the optimized conditions 
described above, and immunoprecipitates were resolved using SDS‐PAGE, and 
subjected to Coomassie staining and western blotting in parallel. As shown in Fig.7, 
SLX4 was detected by western blotting in both of the SLX4 precipitates but not in the 
IgG control precipitate. Although in the western blot the SLX4 band migrated to the 
expected molecular weight, Coomassie staining showed a range of bands that could 
correspond to SLX4 and perhaps modified forms of this protein. In both SLX4 
immunoprecipitates (plus and minus MMC), there were two strong bands that were 
not in the IgG control, and that could have been SLX4. One migrated at 250 kDa (C and 
3 and the second ran slightly more slowly at around 300 kDa (A and B). Neither of 
these bands was perfectly superimposable on the SLX4 western blot (Fig.7). Therefore, 
it is likely that the Coomassie band corresponding to SLX4 was a weaker band in 
between the two strong bands. Nonetheless, the immunoprecipitation worked, as 
tryptic  petides  corresponding  to  SLX4  were  identified  in  both  bands  by  mass 
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spectrometry analysis. The lower migrating bands (C and D) were not only identified as 
SLX4 with protein coverage of 40% and 45% for untreated and treated cells 
respectively, but multiple phospho‐sites were detected. 
 
 
My first interest was to look for phospho‐peptides with SQ or TQ motifs as these are 
the preferred motifs for the ATM/ATR kinases (Kim, Lim et al. 1999) and I expected 
that any such phospho‐peptides would be enriched after DNA damage. Three SQ/TQ 
phospho‐sites were identified in SLX4 where the abundance ratio between cells 
treated with MMC versus untreated cells was above 1, SRDCSSQTQISSLR, 
GGTSQVGSPTLLSPAVPSK, EGSLPHSDDAGDYEQLFSSTQGEISEPSQITSEPEEQSGAVR (Fig.8). 
 
None of them belongs to known SLX4 domains, but the first peptide is conserved 
among closely related eukaryotes (Fig.8). 
 
 
As well as ATM/ATR phospho‐dependent sites, I identified several constitutive Ser‐Pro 
(SP) and Thr‐Pro (TP) sites which could be phosphorylated by any of the proline‐ 
directed kinases in cells including MAP kinases or cyclin‐dependent kinases (CDKs) for 
example (Fig.9). Four phospho‐sites (contained in peptides 11, 14, 17, 20) conform to 
the most stringent consensus sequence (S/T‐P‐X‐R/K) for CDKs (Holmes and Solomon 
1996; Songyang, Lu et al. 1996). Many of the members of this class of protein kinase 
are activated at specific points of the cell cycle to enable specific cell cycle transitions 
by phosphorylating cell cycle‐specific targets (Vermeulen, Van Bockstaele et al. 2003). 
Phosphorylation of SLX4 in this manner raises the possibility of cell cycle dependent 
regulation of SLX4. 
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Figure 7: Large scale affinity purification of human SLX4. 
HEK293 cells were lysed in  buffer  containing  300mM  NaCl,  protease  and  phosphatase 
inhibitors. Cell lysates were subjected to immunprecipitation with sheep  anti‐SLX4 
antibodies or sheep anti‐GFP antibodies (IgG). Left panel: Coomassie staining. Right panel: 
western blot using antibodies against SLX4. Bands around 50 kDa and 25 kDa (*) are the 
heavy and light chain of antibodies  respectively. 
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Figure 8: SLX4 phospho‐SQ/TQ sites that increase in abundance after MMC treatment. 
 
Upper panel: list of SLX4 peptides found to be phosphorylated on one or more SQ/TQ motifs 
after MMC treatment. Middle panel: approximate positions of SQ/TQ residues (*) on human 
SLX4 and sequence  alignment  showing  conserved  phospho‐SQ/TQ  motifs  from  different 
species. Lower panel: alignment of region of SLX4 harboring the phospho‐SQ/TQ motifs. 
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Figure 9: Identification of putative CDK (SP/TP) residues on SLX4 by phospho‐mapping 
analysis. Upper panel: approximate positions of SP/TP residues on SLX4, showed by red 
asterisks (*). Lower panel: list of peptides found to be phosphorylated on one or more SP/TP 
residues. Green check marks indicate peptides with the most stringent consensus sequence for 
CDKs. 
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3.2.3 Interaction of SLX4 with MUS81‐EME1 is cell‐cycle regulated. 
 
In the western blot analysis of the large scale SLX4 immunoprecipites for phospho‐ 
mapping shown in Fig.7, I also checked the precipitates for known SLX4 interactors 
including XPF and MUS81. As shown in Fig.10, the amount of XPF in SLX4 precipitates 
was similar before and after treatment of cells with MMC. However, the level of 
MUS81 was drastically reduced after exposure of cells to MMC. To investigate further, 
I immunoprecipitated SLX4 from HEK293 cells treated with a range of DNA damaging 
agents: mitomycin C (MMC), camptothecin (CPT), hydroxyurea (HU) and ionizing 
radiation (IR). MMC induces intrastrand and interstrand crosslinks, whereas 
camptothecin inhibits the DNA topoisomerase I and consequently provokes collisions 
between the replication fork and topoisomerase‐I cleavable complexes (Liu, Desai et 
al. 2000). The ribonucleotide reductase inhibitor HU blocks DNA synthesis by 
“starving” DNA polymerase at replication forks of dNTPs (Skoog and Bjursell 1974). 
Finally IR targets DNA by inducing double strand breaks. The interaction between XPF 
and SLX4 was not affected at any level by any of these treatments (Fig.11A). The 
situation for MUS81 was dramatically different. Exposure of cells to MMC, CPT, HU and 
even IR reduced the level of MUS81 detected in SLX4 precipitates to the extent that 
prolonged exposure of films was needed to detect MUS81 (Fig.11A). The levels of 
MUS81 in cell extracts was largely unaffected by the genotoxic insults (Fig.11B). 
 
There are two main possibilities to explain dissociation of MUS81 from SLX4 after 
treatment of cells with genotoxins. DNA damage‐induced signaling may induce 
dissociation of the two proteins, by ATM/ATR‐dependent phosphorylation of either 
protein, for example. Alternatively it may be that the interaction of MUS81 and SLX4 is 
cell cycle regulated, and the genotoxins are simply arresting cells at a stage where SLX4 
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interacts less well with MUS81. To distinguish between these possibilities I separated 
cells according to cell cycle stage by counterflow centrifugal elutriation (CCE), a 
technique that does not rely on drugs to synchronize cells. The key principle of CCE is 
that cells at different cell cycle stages have different sizes; more precisely, cells in G1 
stage (2n DNA content) are smaller than to cells in S phase which are in turn smaller 
than cells in G2 phase . Cells are centrifuged in a special rotor and smaller cells (G1) 
sediment first, followed by cells in S and G2 phase. As shown in Fig.12A, I collected 
fractions, corresponding to cells in G1, S, and G2 phase which were first stained with 
propidium iodide and subjected to FACS analysis to check DNA content which is a 
readout of cell cycle stage. Extracts from the different fractions were subjected to 
immunoprecipitation with antibodies against SLX4. Western blotting of precipitates 
revealed that binding of XPF with SLX4 was constant throughout the cell cycle 
(Fig.12B), whereas the interaction between SLX4 and MUS81 was almost completely 
absent during G1 and early S phase (fractions F1‐F3) but became apparent towards the 
end of S‐phase and beginning of G2 phase (fractions F4‐F6). Taken together these 
experiments strongly suggest that the interaction of SLX4 and MUS81‐EME1 is 
regulated in a cell cycle‐dependent manner. 
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Figure 10: SLX4‐MUS81 is reduced in cells exposed to MMC. 
 
Large scale SLX4 immunoprecipitates, as described in Fig. 3, were subjected to western blot 
analysis with the antibodies indicated.  IgG: sheep anti‐GFP (negative control). 
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Figure 11: SLX4‐MUS81 interaction is affected by different genotoxins. 
 
HEK293 cells were treated with mitomycin C (MMC; 200ng/ml), camptothecin (CPT; 2μg/ml), 
hydroxyurea (HU; 2mM), or Ionizing Radiation (IR; 10 Gy). Cells were lysed and SLX4 
immunoprecipitates were analyzed by western blotting with the antibodies indicated (A). 
Expression of proteins in whole cell extracts was examined by western blotting (B). 
70  
 
 
Figure 12: SLX4‐MUS81 interaction is regulated throughout the cell cycle. 
 
Cells were fractionated according to size by counterflow centrifugal elutriation (CCE) resulting 
in 6 fractions. For each sample the DNA content was measured by flow cytometry (A). Samples 
were then lysed and anti‐SLX4 precipitates were subjected to western blotting with the 
antibodies indicated (B). 
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3.3   DISCUSSION AND FUTURE WORK 
 
 
In this chapter, I described the identification of in vivo sites of phosphorylation on 
human SLX4. 
SLX4 appears to be phosphorylated in response to DNA damage on at least three 
ATM/ATR‐consensus sites (SQ/TQ motifs) (Fig.8). It is perhaps surprising that I only 
identified three sites of SQ/TQ phosphorylation in human SLX4 given that at least six 
SQ/TQ sites were identified in yeast Slx4 (Flott et al., 2007). None of the three SQ/TQ 
phospho‐sites identified in human SLX4 are located in any of the known functional 
domains in SLX4. However, of these sites, Thr1273 was previously found by another 
team in a global analysis (Mu et al. 2007) and I noticed that this residue is conserved in 
many SLX4 orthologues, suggesting that it is of functional importance. Thr1273 does 
not reside in any of the known modular SLX4 domains, and so it is difficult to predict 
functional consequences. However it is possible that the three dimensional folding of 
SLX4 might bring Thr1273 in close proximity with SLX4 interacting proteins. In the 
meantime phospho‐specific antibodies have been raised against the sites identified in 
this study and these are currently being tested. 
 
 
It is  possible  that under the  conditions  I used in my experiments  I  missed some 
phospho‐sites, for example because the relevant tryptic peptides are too large. It 
might also be that the phospho‐forms of SLX4 bind very tightly to chromatin and are 
not made soluble by my lysis conditions, in this regard I could use a denaturant in the 
lysis buffer which could be dialysed away before immunoprecipitation. It would be 
interesting to treat cells with another cross‐linking agent that induces only inter‐strand 
crosslinks like SGJ‐136 (Pepper, Hambly et al. 2004), as most the lesions induced by 
72  
MMC are mono‐adducts. As future work, I would also like to scale up even further, and 
to use proteases other than trypsin. Testing the ability of SLX4 bearing mutations in 
the phospho‐sites I identified to rescue the defects in SLX4‐/‐ MEFs would also be 
relevant to understand the function of this posttranslational modification. 
Although I only identified three phospho‐SQ/TQ motifs, I found a relatively large 
number of SP/TP sites in SLX4. These could be targeted by proline‐directed protein 
kinases such as MAP kinases, DYRK isoforms, for example or CDKs. It will be important 
to raise antibodies against these sites and to study the cell cycle dependence. In this 
regard, antibodies have been raised against one of the residues identified in my 
experiment: Ser1453 (Fig.9, peptide 17), because it is interesting for several reasons. 
Previous work carried out in this laboratory identified a physical interaction between 
PLK1 and SLX4. PLK1 belongs to the Polo‐like kinase family that plays essential roles in 
different stages of mitosis and cytokinesis, including the regulation of centrosome 
maturation and spindle assembly (Donaldson, Tavares et al. 2001). PLK1 has a polo box 
that binds to subsets of phospho‐SP/TP sites and the consensus polo box binding motif 
for PLK1 is S‐pS/pT‐P. In this light, SLX4 has four residues that look like polo box 
binding sites, and one of these is Ser1453. When this residue is mutated to Ala, the 
interaction between SLX4 and PLK1 is abolished (data not shown), so it appears that 
CDK phosphorylation of SLX4 creates a docking site for PLK1. Future studies could be 
carried out to investigate the functional significance of this phosphorylation. An article 
recently published by Steve West’s laboratory, showed that SLX4‐MUS81 association 
increases in S/G2 and that the interaction is dependent on CDKs and PLK1 activity but 
the mechanisms and consequences for DNA repair are unclear. After treating cells 
with genotoxins such as MMC, CPT, and HU, my data showed a reduction of MUS81 
levels in SLX4 immunoprecipitates. It is known that these drugs create DNA damages as 
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well as arresting cells during S phase. However, cell-cycle experiments by using the CCE 
technique that does not create any DNA damage in cells, showed that MUS81-SLX4 
interaction was more prominent during late S, G2 phase. It is possible that the 
dynamism in the MUS81-SLX4 binding is due to a combination of cell cycle progression 
and an active disruption of the interaction. As future goal it will be important to 
investigate this hypothesis by analyzing the FACS profile of cells treated with MMC, HU 
and CPT to check at which cell cycle stage they arrest. Finally, in the future it would 
be interesting to see which residues are implicated in the SLX4‐MUS81 interaction, 
whether  they  are  all  CDKs  substrates  or  the  binding  is  also  affected  by  the 
phosphorylation   mediated   by   ATM/ATR,   and   analyze   whether   MUS81   post‐ 
translational modifications also contribute to enhancing the interaction. 
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4 IDENTIFICATION OF NOVEL SLX4‐INTERACTING PROTEINS 
 
 
 
4.1 INTRODUCTION 
Our lab previously carried out a large‐scale SLX4 purification from HEK293 cells 
overexpressing GFP‐tagged SLX4. This resulted in the identification of three different 
endonucleases (XPF/ERCC1, MUS81/EME1, SLX1), TRF2‐RAP1, MSH2‐MSH3, PLK1 and 
C20orf94 (Muñoz et al. 2009). However, this approach can mask weaker interactions 
and overexpression can titrate out low abundance interactors. Since I had 
immunoprecipitated endogenous SLX4 for phospho‐mapping, I decided to use the gel 
from the same experiment to identify new SLX4‐interacting proteins. 
 
 
4.2 RESULTS 
 
 
4.2.1 Mass  spectrometric  identification  of  proteins  interacting  with 
endogenous SLX4: SCF complex 
Fig.7 shows the gel on which I ran large scale anti‐SLX4 immunoprecipitates. I 
subsequently cut each lane into slices which were subjected to tryptic digest and the 
resulting peptides were analysed by mass fingerprinting. This experiment revealed 
most of the known SLX4‐interacting proteins, but I also identified two components of 
the canonical SCF complex: FBXO11 and CUL1. (Table 4) SCF is a multisubunit protein 
ligase (E3) that belongs to a family of Cullin‐RING ligases (CRLS). The canonical SCF is 
composed of an enzymatic core that contains CUL1 and the RING protein RBX1. At the 
N‐terminal CUL1 binds to its adaptor protein SKP1, the latter interacts with an F‐box 
family member (in this case FBXO11) that confers substrate specificity (Petroski and 
Deshaies 2005). 
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Table 4: Proteins interacting with endogenous SLX4 in HEK293 cells identified by mass 
fingerprinting.  Lysates from anti-SLX4 immunoprecipitates have been run on a SDS-PAGE gel and  
the gel has been stained with Colloidal Coomassie Blue. Each lane has been cut into slices, digested 
with trypsin and the resulting peptides analysed by mass fingerprinting. Proteins found in the same 
lane have been grouped together in the table. Proteins found in more than one lane, appear 
multiple times in the corresponding groups.
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I first wished to confirm these interactions. HEK293 were lysed in a buffer containing 
protease, phosphatase and deubiquitinase inhibitors (iodoacetamide), then SLX4 was 
immunoprecipitated from the extract using anti‐SLX4 antibodies and western blotting 
against FBXO11 and CUL1 was performed. The analysis confirmed both interactions, as 
I found bands at the expected molecular weight: around 103kDa for FBXO11 and 
around 89kDa for CUL1 (Fig.13). The other two components of the SCF complex (SKP1 
and RBX1) did not appear in the mass spectrometric analysis, but nonetheless RBX1, 
but not the SKP1 adaptor protein, was detected when SLX4 precipitates were probed 
with the relevant antibodies (Fig.13). 
 
 
Cullins need to be NEDDylated to be active (Saha and Deshaies 2008). NEDD8 is a small 
protein that is more than 50% identical to ubiquitin. Protein neddylation requires the 
action of an E1 NEDD8 Activating Enzyme (NAE) and an E2 NEDD8 Conjugating Enzyme 
(Gong and Yeh 1999). In the SCF complex, NEDD8 is reversibly conjugated to a 
conserved Lys that resides in close proximity to the RING‐binding region of CUL1 (Wu, 
Chen et al. 2000). It has been reported that the covalent attachment of NEDD8 
enhances CUL1‐dependent ubiquitin‐ligase activity in vitro (Ohh, Kim et al.  2002). 
When cells are treated with MLN4924, the molecule binds to and inhibits the NAE, 
therefore it compromises the ubiquitination of SCF‐target substrates (Fig.14). I 
hypothesized the interaction of CUL1 with SLX4 might control SLX4 complex stability 
and to verify this I tested the effect of treating cells with MLN4924, an inhibitor of the 
NEDD8 activating enzyme (Soucy, Smith et al. 2009). Cells were exposed to MLN4924 
for 6 hours before lysis, and extracts were subjected to SLX4 immunoprecipitation. 
As shown  in  Fig.15A,  exposure  of  cells  to  MLN4924  resulted  in  an  increase  in  
CUL1 electrophoretic mobility which others have shown to reflect CUL1 de‐neddylation 
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(Lee, Sweredoski et al. 2011; Zhao, Xiong et al. 2012). However the stability of SLX4 
or the associated endonucleases was unaffected (Fig.15B). 
4.2.2 SLX4 interacts with the E3 ubiquitin ligase UBR5 
 
UBR5, an E3 ubiquitin‐protein ligase which is a component of the N‐end rule pathway 
((Varshavsky 2011), was also detected by mass fingerprinting of SLX4 
immunoprecipitates. UBR5 recognizes and binds to proteins bearing particular N‐ 
terminal residues, leading to their ubiquitination and subsequent degradation. UBR5 
has also been shown to regulate DNA damage responses by controlling RNF168 
stability (Gudjonsson, Altmeyer et al. 2012). I confirmed the interaction of SLX4 with 
UBR5 by western blotting. In SLX4 immunoprecipitates, I detected a band of the 
expected molecular weight for UBR5 (Fig.16A); however, in UBR5 immunoprecipitates 
I found only one of the most slowly migrating SLX4 bands (Fig.16A, asterisk). This was 
an intriguing observation, as SLX4 always exists as a series of bands on SDS‐PAGE; the 
nature of these different species is not clear but they could represent post‐ 
translationally modified forms of SLX4. 
 
 
I wished to further verify the SLX4‐UBR5 interaction. In this light, UBR5 was depleted 
from HEK293 cells using three separate siRNAs. As shown in Fig.16B, western blotting 
cell extracts showed that these siRNA species cause a major reduction in UBR5 
expression. I found that siRNA 1 abolished the UBR5 band in SLX4 precipitates 
(Fig.16C). 
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Figure 13: SLX4 interacts with components of the SCFFBXO11  complex. 
 
HEK293   cells   were   lysed   and   subjected   to   SLX4   immunoprecipitation.   Precipitates   were 
subjected to western blot analysis with the antibodies indicated. 
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Figure 14: Schematic view of MLN4924 inhibition. 
 
The SCF complex promotes the poly‐ubiquitination of target substrates leading to their 
degradation. The conjugation of the ubiquitin‐like protein NEDD8 to CUL1 (neddylation), 
stimulates the ubiquitin transfer from SCF‐bound E2 to the substrate lysine and the 
polymerization of the ubiquitin chain. Neddylation is a three steps pathway, where in the first 
step NEDD8 binds to the E1 NEDD8‐activting enzyme (NAE). The competitive inhibitor, 
MLN4924 disrupts the interaction between NEDD8 and NAE, therefore blocks the neddylation 
of the SCF complex and prevents the ubiquitination of SCF substrates. 
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Figure 15: MLN4924 does not affect the interaction of SLX4 with XPF, MUS81 or SLX1. 
 
HEK293 cells were treated, or not with MLN4924 (3μM; 6 hr). The expression levels  of  the 
indicated proteins were analyzed in whole cell extracts by western blotting (A). Extracts were 
subjected to SLX4 immunoprecipitation and  precipitates  were  subjected  to  western  blotting 
with the indicated antibodies (B). 
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Figure 16: SLX4 interacts with the UBR5 E3 ubiquitin ligase 
 
(A) HEK293 extracts were subjected to immunoprecipitation with either anti‐SLX4 or anti‐UBR5 
antibodies and  western  blot analysis  with indicated  antibodies  was  performed. Asterisk 
indicates the SLX4 slow migrating band. (B) Cells were transfected with three separate UBR5 
siRNAs (10, 25 or 50 nM) or with a control (scramble siRNA 50 nM). (C) Cells were transfected 
with UBR5 siRNA number 1 (10 nM), and SLX4 was immunoprecipitated from UBR5‐depleted 
extracts and western blotting analysis of the indicated proteins was performed. 
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4.3 DISCUSSION AND FUTURE WORK 
 
In this chapter I identified two E3 ligases in SLX4 immunoprecipitates: UBR5 and 
SCFFBXO11 and confirmed the interactions by western blotting. It is still unknown 
whether SLX4 directly binds to these ubiquitin ligases or whether the interaction is 
through one of the SLX4‐binding partners. Although the meaning of these interactions 
is still a conundrum, some hypothesis can be made, based on the literature. 
 
 
 
Regarding UBR5, it has been reported an involvement in the DNA damage response, by 
targeting RNF8 and RNF168 for proteasomal degradation (Gudjonsson et al. 2012). 
RNF8 and RNF168 are two E3 RING ligases that are recruited to the chromatin after 
double strand breaks. They modify the histone variant H2A and H2AX by adding K63 
linked chains, which induce the recruitment of downstream effectors leading to the 
repair of the DNA damage (Bartocci and Denchi 2013). UBR5 controls an excessive 
spreading of ubiquitinated chromatin at damaged chromosomes, by contributing to 
the degradation of RNF8 and RNF168. A recent study revealed that the shelterin 
component TRF2 is involved in preventing the DNA damage response at telomeres, by 
blocking the signaling cascade at the level of RNF168 (Okamoto, Bartocci et al. 2013). 
Interestingly the same team found UBR5 in TRF2 immunoprecipitates. Given that TRF2 
is one of the components of the SXL4 scaffold and that SLX4 localizes on telomeres 
(Svedsen et al. 2009; Wilson et al. 2013), it is possible that the SLX4‐UBR5 interaction is 
mediated by TRF2. It would be interesting to see whether the SLX4‐UBR5 interaction is 
compromised in TRF2 depleted cells. 
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UBR5 could also directly bind and modify SLX4. Western blot analysis of UBR5 
immunoprecipitates using antibodies against SLX4, showed that only a slow migrating 
form of SLX4 binds to the ligase and it would be interesting to test whether this 
corresponds to an ubiquitinated form of SLX4, by treating samples with non‐specific 
deubiquitinases. 
 
 
Regarding SCFFBXO11, it is part of a family of Cullin-RING ligases (CRLs). Human cells 
express seven different cullins and each of them nucleates different multisubunit 
complexes. CUL1-based E3 ligases are called SCF ubiquitin ligases. The canonical SCF is 
composed of CUL1, the adaptor protein SKP1, the RING containing protein RBX1, and 
the F‐BOX protein that confers substrate specificity and varies depending on the 
target substrate (Fig.14). Preliminary experiments showed that SLX4 interacts with 
FBXO11, RBX1, and CUL1. Interestingly the fraction of CUL1 that co-
immunoprecipitates with SLX4 is neddylated, which suggests that the 
SCFFBXO11 complex binds to the scaffold as an active E3 l igases. Suprisingly, 
SLX4 did not interact with the adaptor SKP1. It is known that another cullin, CUL3, 
which is part of the CRL3 (Culling-RING ligase 3) uses as adaptor BTB‐domain 
containing proteins (Petroski et al., 2005) and SLX4 contains a BTB domain. 
Moreover the mass spectrometric analysis of SLX4 immunoprecipitates did not find 
any peptide corresponding to CUL3, so it could be possible that not only CUL3, but 
also CUL1 binds to BTB‐proteins and that SKP1 is not the only adaptor for CUL1. If 
the same assembly of the complex was present in mouse cells, it would be interesting 
to analyze the CUL1‐FBXO11 interaction in Slx4‐/‐ cells. 
As for UBR5, SCF could also be involved in the binding of other SLX4 component or the 
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interaction could be mediated through a still unknown ubiquitinated protein that binds 
to the UBZ4 domains of SLX4. An extensive screening of all the SLX4 partners should be 
performed to address this question. 
85  
5 DOES SLX4 INTERACT WITH MSH2‐MSH3? 
 
 
5.1 INTRODUCTION 
MSH2‐MSH3 is a heterodimer which functions by recognizing insertion/deletion loops 
in the mismatch repair, gene conversion, or single strand annealing pathways. 
Although MSH2‐MSH3 was detected in mass fingerprinting analysis of precipitates of 
tagged and overexpressed human SLX4 (Svendsen et al. 2009), the mass fingerprinting 
analysis described in section 3, didn’t detect neither MSH2 nor MSH3 in SLX4 
precipitates. Although this might be due to the stringent conditions used for the 
immunoprecipitation (300mM NaCl), it might be that the reported interaction of SLX4 
with MSH2‐MSH3 is an artifact of overexpression. I decided to test if endogenous SLX4 
interacts with MSH2‐MSH3. 
 
5.2 RESULTS 
 
5.2.1 Analysis of SLX4‐MSH2/3 interaction 
 
Western blotting of anti‐SLX4 immunoprecipitates revealed the presence of both 
MSH2 and MSH3 (Fig.17). In order to discriminate which subunit of the MSH2‐MSH3 
complex interacts with SLX4, I used a yeast two hybrid assay. This method has 
advantages over other biochemical approaches. It assays protein-protein direct 
interactions, it requires only the cDNA of the gene of interest in contrast to high 
quantity of cell lysate and good quality of antibodies for immunoprecipitation 
experiments. Moreover weak and transient interactions are detected and amplified. 
However, one of the disadvantages is that this system makes use of S. cerevisiae as a 
host; for this reason, a yeast protein could bridge the interaction between proteins of 
interested. As shown in Fig.18, the yeast-two-hybrid experiment revealed that MSH2, 
and not MSH3 interacts with SLX4. I next used different SLX4 deletion fragments to 
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map the SLX4 region binding to MSH2. This revealed that the X4 peptide of SLX4 
(residues: 1‐792) interacts with MSH2 (Fig.19). Surprisingly, MSH2 didn’t interact 
with any of the fragments (X1, X2, X3) that narrow this region down further. 
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Figure 17: SLX4 interacts with the MSH2/MSH3 complex. 
 
HEK293  extracts  were  subjected  to  immunoprecipitation  with  either  anti‐SLX4  or  anti‐MSH3 
antibodies and western blotting analysis was performed with the indicated antibodies. 
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Figure 18: Yeast two hybrid assay shows that SLX4 directly interacts with MSH2. 
 
SLX4 was cloned into activation domain vector (AD) and MSH2 or  MSH3  into  GAL4  DNA‐ 
binding domain vector (BD). To select both vectors, cells were grown  on  selective  medium 
lacking LEU and TRP. Cells were then replica plated to medium lacking LEU, TRP, and HIS, to 
test for activation of HIS3 reporter gene, and then replica plated on x‐gal membrane to test for 
LacZ reporter gene activity. 
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Figure 19: Yeast two hybrid assay with MSH2 and SLX4 deletion SLX4 fragments. 
 
A: schematic view of the SLX4 sequence and positions of the different fragments. 
B: yeast two hybrid analysis between MSH2 and different SLX4 fragments. 
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5.3   DISCUSSION AND FUTURE WORK 
 
In this section I confirmed by yeast-two-hybrid assay that SLX4 interacts with the 
MSH2‐MSH3 complex through MSH2. I also found that the N‐terminal region of SLX4 
is involved in the binding, but none of the SLX4 truncation constructs that narrow 
this region down further interacted with MSH2. There are several possibilities that 
could explain this result.  It is possible that the SLX4 fragments are not expressed in 
yeast or that they are misfolded. However it could be that MSH2 might contact 
multiple points in SLX4. The BTB domain of SLX4 mediates homodimerization and 
it might be that the MSH2 binding site on SLX4 is only formed after SLX4 dimerizes. 
This would be more complicated than the interaction between SLX4 and its other 
components (SLX1, XPF, and MUS81 for example) where small interacting regions 
could be defined and single point mutations are capable of abolishing binding. 
 
 
In yeast S. cerevisiae, Msh2‐Msh3 helps the nuclease activity of Rad1‐Rad10 (XPF‐ 
ERCC1) during gene conversion and single strand annealing. Although in human it has 
not been reported an involvement of SLX4 in SSA, it could be possible that SLX4 plays a 
role in this pathway, given that SLX4 binds both to MSH2‐MSH3 and XPF‐ERCC1. If I 
could identify mutations that abolish binding of SLX4 to MSH2, in the future I could 
carry out rescue experiments to test the effect of SLX4‐MSH2/3 interaction on ICL 
repair and single‐strand annealing. 
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